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CHAPTER 1 
GENERAL INTRODUCTIOO 
IMMUOOSURVEILIANCE OF CANCER 
1.1 Introduction 
The demonstration of specific immunity to foreign cell surface antigens 
provided the experimental basis for the theory of immunosurveillance of tumor 
cells. First proposed by Thomas (1) and expanded by Burnet (2), this theory 
states that the immune system maintains "surveillance" over the body by 
rejecting small clones of malignant cells that are antigenically sufficiently 
distinct from normal cells. 
Tumors can be induced by irradiation, chemical substances, viruses, or 
arise spontaneously in vivo. Depending on the origin of tumor cells, various 
types of "foreign" antigens can be expressed which are generally termed 
tumor-associated antigens (TAA) (for review see 3). Tumor-specific 
transplantation antigens (TSTA) and viral capsid proteins located at the cell 
surface of chemically or virally induced tumors, respectively, are recognized 
by the immune system (3). However, not all TAA are recognized, as for 
instance, oncofetal gene-products or T-cell antigens that are "hidden" in the 
nuclei of tumor cells. Spontaneous tumors have very little in vivo 
immunogenicity (3). 
The cellular immune response comprises two major components: adaptive 
immunity and natural immunity. Adaptive immunity is governed by T cells which 
are antigen-specific (4,5), i.e. foreign antigens expressed on tumor cells 
are recognized in the context of self-major histocompatibility complex (MHC) 
determinants by the T~cell receptor (TCR) of T lymphocytes. Experimental 
results showed that tumor cells can induce activation and proliferation of 
cytotoxic T lymphocytes (CTL), which in turn lyse these tumor cells (3,5). 
Natural or MHC-unrestricted immunity is expressed by natural killer (NK) 
cells, monocytes;macrophages and granulocytes (4,5). 
Non-immunogenic tumor cells, may be recognized and destroyed by NK 
cells (5). These NK cells can lyse tumor cells in vitro without prior 
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activation. Biological response modifiers (BRM) such as interleukin-2 (IL-2) 
and interferons (IFN) enhance NK cell lysis. 
This chapter deals with the different types of cytotoxic lymphocytes and 
their role in immunosurveillance. The membrane structures of these cells 
involved in activation and recognition in relation to their CTX against tumor 
cells are discussed. Finally, some possibilities _how to modulate lytic 
functions ofT and NK cells with the ultimate aim of immunotherapy of cancer 
patients, are suggested. 
1.2 Classification of cytotoxic lymphocytes 
Cytotoxic lymphocytes can be classified in different types based on 
their lytic mechanisms and the expression of cell surface cluster 
differentiation (CD) antigens (fot review, see 6). The most extensively 
studied classes of cytotoxic lymphocytes are: (1) MHC class I-restricted CTL 
expressing TCR~~/CD3 and CDS antigens; (2) MHC class II-restricted CTL 
expressing CD3 or CD4 antigens; (3) MHC-unrestricted T cells expressing 
TCRy&+/CD3 but not CD4 or CDS antigens; and (4) MHC-unrestricted NK cells 
which lack the expression of TCR/CD3, CD4 and mostly CDS antigens (Table 1.1). 
The MHC-restricted CTL recognize target cells via their TCR~~ (see section 
1.1). MHC-unrestricted T cells recognize target cells via other receptors than 
the "classical" TCR (as detailed in section 1.3). MHC-restriction has not been 
shown yet for TCRy&+/CD3+4-S- T cells. The MHC-unrestricted NK cells recognize 
target cells via an as yet undefined receptor. 
1.3 How do T cells recognize and bind foreign structures? 
How can a great variety of foreign structures on cell surfaces be 
recognized by the T-cell? The answer to this question has emerged during the 
last decade and appeared to involve 2 groups of molecules: MHC determinants on 
the target cell and the TCR on the effector cell (for review see 7). T 
lymphocytes recognize foreign antigen, e.g. degraded virus particles, only in 
the context of self-MHC determinants. These CTL are "antigen-specific". 
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TABLE 1.1 
GENERAL CLASSIFICATION OF CYTOTOXIC LYMPHOCYTES 
Ehenotype cell type 
CTL CTL CTL NK 
C02 + + + + 
CD3 + + + 
CD4 + 
CDS + -1+ 
CD16 +1- + 
TCR cxl3 cxl3 yeS 
lytic mechanism 
MHC class I 
restricted + unknown 
cytolysis 
MHC class II 
restricted + unknown 
cytolysis 
MHC 
unrestricted + + + 
cytolysis 
ADCC +1- + 
LDCC + + + unknown 
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However, in allogeneic combinations, e.g. in transplantation immunity 
or in a mixed lymphocyte culture (MLC), the target cell MHC determinants are 
recognized as foreign by CTL which are called "alloreactive" T lymphocytes. 
It has been proposed that MHC proteins act as a receptor for a foreign 
peptide, thereby holding it in a position that favors detection by 
antigen-specific CTL (8,9). It appeared that MHC proteins select similar 
peptide sequences from diverse antigens for presentation to these CTL (10). 
With respect to allospecific T cells, it was suggested that a foreign MHC 
molecule looks like a "self" molecule carrying an antigenic peptide (8). Small 
differences from the "self" sequence are enough to trigger an allo-immune 
reaction, i.e. recognition by the TCR and subsequent activation of the CTL. 
The TCR is composed of two polypeptide chains, TCRtt and TCR~, which 
together determine the specificity of the T-cell (11-13). The ~chain gene is 
composed of variable (V), diversity (D), joining (J), and constant (C) region 
segments in the germ line configuration (14-16). The tt chain gene contains V, 
J and C region segments, but it is not clear whether it contains D segments. 
Rearrangement of these gene segments is a prerequisite for the functional 
expression of the TCR. These regions join through rearrangement during T-cell 
ontogeny and different combinations of the V, (D), J and C DNA segments define 
their antigen specificity. The structural diversity of TCR is determined by 
(a) the combination of V, (D), J and C DNA segments, and (b) the different 
sites at which the gene segments are joined. Both chains are required for 
recognition of foreign structures. The TCR is non-covalently associated with 
the CD3 complex which is involved in the transmission of activation signals 
(12,16,17). The CD3 complex is composed of at least 4 invariable 
non-covalently linked polypeptide chains y, o, E and ~ (18,19). It has been 
suggested that the CDo chain transduces activation signals (19,20). 
Recently, a CD3 complex was found on CD4_8_ T lymphocytes that did not 
express the TCRtta heterodimer (21-24). These cells appeared to express CD3 in 
association with: 
(a) a disulphide heterodimer consisting of a 40K y chain and a 40K o chain; 
(b) a non-disulphide heterodimer consisting of a 40K y chain and a 40 K 
o chain, or 
(c) a non-disulphide heterodimer consisting of a 55K y chain and a 40 K 
o chain. 
The TCRy polypeptide component of the disulphide form is encoded by a 
gene that utilizes the Cy1 gene segment, while the non-disulphide form is 
encoded by a gene that utilizes the Cy2 gene segment (25). The differences in 
molecular weight between the 45 and 40K y-proteins is primarily due to 
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differences in glycosylation (26). 
The TCR y and o genes are essentially similar in structure to those 
encoded by the TCR ~and ~genes, although with less variability. The antigen 
receptors expressed on different types of cytotoxic lymphocytes are 
schematically depicted in Figure 1.1. 
T -cell receptor 
---
CD3-receptor 
~ disulphide binding 
5 
,...---"'( 
,..----0~ 0 
e: 
y 
---?; 
? 
Figure 1.1 Antigen receptors on different types of cytotoxic lymphocytes. The 
T-cell receptors (TCR) are shown in association with a CD3 receptor. For all T 
cells, the CD3 receptor consists of a o, e:, y and ~ chain. The TCR are 
different for the various T cells. CTL express disulphide linked ~-~ chains, 
disulphide linked y-o chains or non-disulphide-linked y-o chains. For NK cells 
an antigen receptor has not been identified yet. 
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1.4 Bow do NK cells recognize and bind foreign structures? 
The cytotoxic activity of 
determinants on their target cells. 
NK cells is not restricted by 
It has been shown that in NK cells 
MHC 
the 
genes encoding a,~,y and & are in the germline configuration. NK cells express 
no TCRa & or y mRNA, and express an aberrant TCR~ mRNA, the product of which 
is therefore not functional. Furthermore, no CD3-like structures have been 
found on NK cells. At present, it is not known which receptor structures on 
these TCR-/CD3 NK cells and their target cells are involved in recognition 
and killing. Recently it has been shown that IgG-Fc receptors (FeR or CD16), 
T200 molecules (CD45) and the receptor for the sheep red blood cells (SRBC or 
C02) are involved in the regulation of cellular cytotoxicity (CTX) of 
TCR-/CD3- NK cells (27-30). We demonstrated that anti-CD16 monoclonal 
antibodies (mAb) can induce lytic activity of target cells (27). In contrast, 
mAb directed against structures associated with the CD45 molecule can block 
NK-cell lysis (31), while anti-CD2 mAb block or induce cytolysis, depending on 
effector-target cell combinations used (29,31 for review, see 32). 
1.5 Mechanisms of cytolysis 
The various types of .cytotoxic cells described in section 1.2 are 
endowed with different lytic mechanisms (for review, see 6). CTX can be 
induced in various ways, depending on the activation process and the 
stimulator cell type (32). TCRa~+/CD3+,4+,s- and CD3+,4-,8+ CTL require 
allostimulation before they are able to exert MHC-restricted CTX. Some 
TCRa~+/CD3+,4-,8+ CTL exert MHC-restricted as well as unrestricted CTX after 
allostimulation (33). In contrast to TCRa~+/CD3+ CTL, TCR-/CD3- NK cells exert 
MHC-unrestricted CTX without any prior ex vivo stimulation. TCR-/CD3 NK cells 
also mediate antibody-dependent cellular cytoxicity (ADCC), i.e. they lyse 
NK-resistant target cells when these are coated with IgG antibodies. Only 
TCR-/CD3- NK cells (34) and some TCRy&-/CD3-4-,8- CTL (27,35) express CD16. 
Like NK cells, these TCRy&+/CD3+,4-,8- CTL can exert MHC-unrestricted lysis of 
target cells but need to be activated, e.g. by IL-2 (21). 
TCRa~ and TCRy& CTL lyse target cells which have been precoated with 
phytohemagglutinin (PHA), i.e. so called lectin-dependent cellular 
cytotoxicity (LDCC). Only those effector cells which have intrinsic lytic 
capacity (activated but not specifically recognizing the target cell) can 
lyse PHA-coated target cells. The lytic mechanisms employed by different 
cytotoxic lymphocytes in vitro are listed in Table 1.1. 
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The mechanism of 
TCR-/CD3 NK cells, is 
in vivo killing, either 
not well understood. As 
by TCR~~+/CD3+ CTL or by 
stated, TCR~~+/CD3+ CTL 
recognize foreign antigens in vitro in the context of MHC determinants (for 
review, see 7). Before recognition of specific antigen and MHC, nonspecific 
conjugate formation between TCR~~+/CD3+ CTL and target cell takes place 
(36,37). The nonspecific adhesion stage is Mg-dependent (38). Recent data 
suggest that in this stage LFA-2 (C02) on the effector cell interacts with 
LFA-3 as its ligand on the target cell (39), or LFA-1 on the effector cell 
interacts with the Inter Cellular Adhesion Molecule-1 (ICAM-1) on the target 
cell (40). After binding a target cell, the TCR~~+/CD3+ CTL becomes activated 
and rapid Ca-mobilization takes place. After the nonspecific adhesion, a 
specific TCR/MHC-antigen interaction takes place followed by programming for 
lysis and the lethal hit. The "programming for lysis" stage is Ca-dependen t. 
Once the lethal hit has been delivered the target-cell-lysis is 
CTL-independent (41). Activation of TCR~~+/CD3+ CTL by the tumor cells also 
induce the expression of interleukin-2 receptors (IL-2R) which are required 
for proliferation. 
Two different models for T-cell lysis are presented in Figures 1.2.1 
and 1.2.2 (42). The currently most common view is that upon specific 
recognition TCR~~+/CD3+ CTL release poreforming molecules in the intercellular 
space between CTL and the target cell. These molecules subsequently attach to 
the target cell and induce cytolysis. However, 2 groups independently showed 
that target cell lysis by TCR~~+/CD3+ CTL does not require exocytosis of 
cytolytic granules containing perforins, esterases or cytolysin (43,44). For 
instance, antibodies that inhibit perforin-mediated cytolysis do not inhibit 
T-cell mediated cytolysis (42). 
An alternative view is that TCR~~+/CD3+ CTL induce the target cells to 
commit suicide. When target cells are presented to TCR~~+/CD3+ CTL, it is 
their nuclear and not the cytoplasmic membrane that is damaged (45) followed 
by rapid DNA fragmentation (46). Recently, it has been shown that 
glucocorticoids can activate an endogeneous suicide process in target cells by 
degradation of chromosomal DNA (47). 
The interaction site on TCR-/CD3 NK cells for their target cell 
structures is unknown but, like TCR~~+/CD3+ CTL, target cell recognition is 
Mg-dependent and effector cell activation is Ca-dependent (48,49). After 
binding of poreforming molecules on the target cell, lysis subsequently takes 
place, even after the effector cells are detached (Figure 1.3) (49). 
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a b 
antigen- receptor 
interaction 
migration 
of granules 
•• 
••• 
·:;.: . 
• 
""3 
··=r 
granules containing poreforming molecules 
poreforming molecules 
antigen I M H C 
T -cell receptor 
CD3-receptor 
c 
lysis of 
the tumor cell 
Figure 1.2.1 Poreforming molecules from CTL can induce lysis of tumor cells. 
After antigen-receptor interactions (a) signals are transduced via the CD3 
receptor, inducing migration of lysosomes to the membrane surface of the CTL 
(b). Binding of poreforming molecules (cytolysins) lead to lysis of the tumor 
cell (c). For this final process of cell lysis the presence of CTL is not 
required. 
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a 
antigen- receptor 
interaction 
•• ... granules 
4 antigen I M H C 
~ T- cell receptor CD3-receptor 
u internal self-destructive mechanism 
b 
induction of 
a self-destructive 
mechanism 
c 
lysis of 
the tumor cell 
Figure 1.2.2 CTL trigger tumor cells to commit suicide. After 
antigen-receptor interaction (a) an internal selfdestructive mechanism is 
triggered in the tumor cell (b), which causes cytolysis (c). The latter step 
can occur without the presence of CTL. 
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a 
undefined 
antigen- receptor 
interaction 
b 
migration 
of granules 
::. granules containing poreforming molecules 
·.·:::: poreforming molecules 
~ undefined antigen 
::::::S:. undefined receptor 
c 
lysis of 
the tumor cell 
Figure 1.3 Poreforming molecules from NK cells induce lysis of tumor cells. 
It is not known which antigen-receptor interactions are involved in 
recognition. Like for CTL, after binding of NK-cells to tumor cells (a) 
internal signals induce migration of lysosomes. containing poreforming 
molecules (cytolysins) (b). Binding of the poreforming molecules to the cell 
surface of the tumor cell (c) induces cytolysis of the tumor cell. Again, the 
latter step can occur without the presence of NK cells. 
1.6 Growth factors 
IL-2, previously termed T-cell growth factor (TCGF), provides the 
necessary signal for the transition of activated T cells from the Gl to the S 
phase of the cell cycle (50). Activation of resting TCR~~+/CD3+ CTL by 
antigens or mitogens leads to the release of several lymphokines, including 
IL-2, and to the induction of IL-2R (51). The interaction between IL-2 and the 
IL-2R is an absolute requirement for proliferation of T and NK cells. Recent 
studies have indicated that TCR-/CD3 NK cells, in contrast to TCR~~+/CD3+ 
CTL, can proliferate for about 2 weeks in response to IL-2 alone, i.e. without 
the need for a separate activation signal (52-54). 
Three types of IL-2R have been identified i.e., a P55 ~-chain with a 
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low affinity for IL-2, a P70 ~chain with an intermediate affinity for IL-2, 
and a P55-P70 tt~ heterodimer with a high affinity for IL-2 (55). On resting NK 
cells, only the IL-2R ~chain is expressed. Upon interaction of IL-2 with the 
~chain the IL-2 tt-chain receptor is induced and functional high affinity 
IL-2R are formed (56). The growth signal is delivered by IL-2 bound to the 
high affinity and not to the low or intermediate affinity receptor (57-59). 
The fate and function of the low-affinity type is unknown. Anti-CD25 mAb, 
called anti-TAC mAb, specific for the IL-2 tt-chain receptor have been produced 
(60,61). Molecular cloning of the TAC antigen has formally proven that this 
receptor (CD25) binds IL-2 (62,63). In addition to its key role in 
proliferation of T lymphocytes, IL-2 also exerts other immune-regulatory 
functions. (see section 1.8.). 
1.7 Oncogenes 
Proto-oncogenes are conserved cellular genes homologous to the 
transforming (one) genes of acute, oncogenic retroviruses (for review, see 
64). It is now widely accepted that upon transcriptional or mutational 
activation proto-oncogenes can function like viral oncogenes. In oncogene 
research, activation refers to the conversion of a non-oncogenic 
proto-oncogene, into a carcinogenic variant. Indeed, mutations in 
proto-oncogenes or alterations in their level of transcription have been found 
in certain tumors. However, mutated proto-oncogenes are structurally different 
from viral oncogenes. Moreover, mutated proto-oncogenes are less efficient in 
transforming rodent cells than viral oncogenes (65). The proto-oncogenes are 
regarded as a subset of a larger group of cellular genes thought to be 
involved in differentiation events and in growth control of cells (66,67). 
The physiological role of some (proto-)oncogenes have been established. 
For example, v-erbB is known to be derived from the normal cellular gene that 
encodes the epidermal growth factor (EGF) receptor (68,69), and the v-sis 
oncogene encodes a growth factor that is structurally and functionally 
homologous to platelet-derived growth factor (PDGF) (70,71). Similarly, the 
v-fms oncogene is probably derived from the gene for the macrophage 
colony-stimulating factor receptor (MCSF) (72). Many oncogene products 
identified as growth factors, influence the expression of other oncogenes. 
For example, the product of v-sis (PDGF) stimulates accumulation of c-myc and 
c-fos transcripts in growth arrested cells (73-76). Other work indicates that 
transforming growth factor ~ (TGF-~) increases the number of cell surface EGF 
receptors (77). Myc-like genes encode nuclear DNA binding proteins that may 
in turn regulate the expression of other oncogenes involved in cell 
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proliferation (78,79). Stern et al (80) suggested a model for the interplay 
of c-myc and e-ras oncogenes in which the ras-like genes induce growth factor 
production, while myc-like genes increase the responsiveness of cells to 
these factors. 
The mechanism(s) by which oncogenes act in the growth-regulating 
processes are not very well understood and remain to be investigated. 
Recently, it has been found that products of ras genes are located at the 
inner surface of the plasma membrane of fibroblast cells and may be involved 
in transduction of extracellular signals (81-84). It has been suggested that 
the e-ras proto-oncogene encodes for a G-protein (81,85), also present in the 
plasma membrane of T cells, and involves the regulation of external signals 
induced by PHA or allostimulation (86). 
The induction of many oncogene transcripts in T cells has been studied 
extensively in vitro. Kelly et al. (87) reported that in the mouse system 
c-myc mRNA levels in PBL can be augmented by mitogenic lectins. We and others 
found similar results for human PBL of healthy individuals (88,89). Possible 
routes of the induction of c-myc expression in normal and malignant 
TCRtt~+/CD3+ and TCR-/CD3- lymphocytes have been described in chapter 5 of this 
thesis. Reed et al (89) showed that in human PHA-stimulated PBL the genes for 
c-fos, c-myc, IL-2 and IL-2R are expressed early, whereas c-myb, N-ras and 
transferrin-receptor (TRF) are expressed later in PHA stimulated PBL. IL-2 
augmented the expression of the genes for c-myb, P53, N-ras and TRF in PHA 
stimulated cultures of PBL, as well as the early genes for c-myc and the IL-2R 
but not c-fos (89,90). 
1.8 Modification of the cytolytic response 
Cytokines involved in proliferation of T and NK cells may also affect 
their CTX and are therefore called BRM. The effects of BRM such as IL-2, IFN 
and OK-432 on the cytolytic response have been extensively studied in vivo and 
in vitro both in man and mice (91-96). 
OK-432 (a streptococcal preparation) can reduce carcinomateus effusions 
in the pleural or peritoneal cavities (97,98). It can affect the immune system 
by activation, increase or restoration of the activities of various immune 
effector cells, or by inhibition or abrogation of its functions (for review 
see 99). Most studies were performed with fresh PBL or with NK-cell enriched 
fractions. Because of the heterogeneity of the responder cell populations it 
is not clear which particular cell types respond to OK-432. TCR-/CD3- NK cells 
are considered most responsive to OK-432, i.e. augmentation of NK-cell 
activity against tumor cells (92,100), but others suggested that OK-432 
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eliminates the suppression of NK-cell activity by monocytes (101). 
~ith the introduction of lymphocyte cloning techniques, it became 
possible to investigate whether TCR~S+/CD3+ T-cell subsets as well as 
TCR /CD3 NK cells can respond to OK-432 (see chapter 6 of this thesis). 
IFN have been classified into 3 categories i.e. ~ (leucocyte), S 
(fibroblast) and y (immune). They posses numerous biological activities, 
including modulation of the immune response as well as antiproliferative 
capacities (94). IFNS strongly augments NK-cell activity against tumor cells 
(96,102). IFNy also enhances the expression of MHC and Ia antigens on various 
cell types (103). Increased MHC expression leads to an increased 
susceptibility to antiviral and antitumor cytotoxic lymphocytes (104-106). 
IL-2 can potentiate IFN-y production by mitogen stimulated T cells. 
IL-2 has been shown to augment the cytotoxic activity of TCR-/CD3- NK 
cells against numerous tumor cell lines (105,107). It augments the CTX of NK 
cells from healthy subjects (108,109) as well as from patients with acquired 
immune deficiency syndrome (110). 
IL-2 can also enhance the lytic activity of fresh PBL against some 
fresh autologous tumor cells (111-114). Such responder cells are called 
"lymphokine-activated killer" (LAK) cells. LAK cells, first described by Grimm 
et al. (114) and Rosenberg et al. (115) were reported to express CD3, CDS and 
CD16 markers. However, the majority of human cells with activated killer (AK) 
activity, as reviewed by Hersey and Bolhuis (32), have now been proven to be 
derived from the TCR-/CD3- 16+ NK cells. These authors suggest that activated 
lymphocyte killing (ALK) defines an activity rather than a distinct effector 
cell population (32). 
The adoptive transfer of LAK cells into mice with established pulmonary 
sarcoma metastases was highly effective in reducing the number (and size) of 
these tumor nodules when combined with separate injections of IL-2 (116). 
These findings provide a rationale for clinical application, i.e. the infusion 
into patients of IL-2 activated lymphocytes together with the systematic 
infusion of IL-2. 
1.9 Cytotoxic lymphocytes and their antitumor reactivity 
~e described that in vitro the interaction between TCR~S+/CD3+ CTL and 
tumor target cells may activate CTL which lead to IL-2R expression, 
proliferation of these CTL and lysis of tumor target cells. Such mechanisms 
were proposed to be operative in vivo to prevent outgrowth of tumor cells and 
are called immunosurveillance (see section 1.1). A concept of a generalized 
immunosurveillance by CTL predicts that 
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(a) tumors that arise in spite of immunosurveillance in normal hosts are 
poorly immunogenic and do not provoke an immune response; 
(b) any clinical or experimental condition associated with depressed T-cell 
immunity will be associated with an increased tumor incidence; and 
(c) many tumors arising in such immunodeficient hosts are immunogenic. 
Thus far, some results obtained in experimental studies support the 
immunosurveillance theory and others argue against it. A phenomenon that has 
been used as an argument against the immunosurveillance theory is the fact 
that a small number of immunogenic tumor cells injected into a syngeneic 
recipient can often escape from immune lysis, whereas a larger number of tumor 
cells is rejected (117,118). A phenomenon which supports the 
immunosurveillance theory is the poor immunogenicity of the majority of 
spontaneous tumors arising in immunocompetent hosts. Another phenomenon which 
supports the immunosurveillance theory is the increased incidence of tumors in 
immunosuppressed patients. In hereditary immunodeficient patients and in 
individuals receiving chronic immunosuppressive therapy after transplantation, 
the incidence of tumors was found to be strongly increased in comparison to 
the general population (119,120). An example of a naturally occuring 
immunodeficiency state associated with an increased incidence of 
is Wiskott-Aldrich syndrome (128-fold increase). In renal 
malignancies 
transplant 
recipients, rece1v1ng immunosuppressive drugs, the incidence of tumors was 
also found to be increased (119,121). Dialysis-patients showed a 26-fold 
increase for non-Hodgkin lymphoma, while for patients with autoimmune diseases 
the increased incidence of tumors appeared to be variable (122). An excess of 
tumors has also been found in patients with an acquired immunodeficiency 
syndrome (AIDS), such as Kaposi's sarcoma, Burkitt lymphoma, reticulum 
sarcoma, cancer of mouth, head and neck, cloaogenic cancer and sometimes 
hepatoma (123-125). Another facet of the immune response is the tumor-induced 
activation of suppressor T cells leading to the inhibition of a CTL response. 
This phenomenon has been demonstrated for melanoma in vitro by Mukherji et al. 
(126,127). 
NK cells were considered to 
participate in the immune response against tumor cells (see section 1.1). Many 
studies have shown that TCR-/CD3- NK cells may inhibit the growth of tumor 
cells in vivo (128). NK activity is strongest in blood and spleen, but 
relatively poor or undetectable in lymph nodes, thymus and bone marrow (129). 
These observations lead to the suggestion that metastases present in blood or 
spleen are the most likely targets for TCR-/CD3 NK cells. The observed 
increased invasiveness and frequency of metastases in patients with diminished 
natural immunity mediated by TCR-/CD3 NK cells or natural antibodies or both 
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(128) support this suggestion. Like CTL-responses, NK-responses can be 
inhibited by suppressor cells or by soluble factors such as prostaglandin E 
(PGE), produced by tumor-activated suppressor cells (130,131). 
What could be the role of TCRyo+/CD3+ CTL in the immune response against 
spontaneous or virus-induced tumors? TCRyo+/CD3+ CTL appear early in the 
ontogeny and may provide protective immunity against viral or bacterial 
infections (132). There is evidence that TCRyo+/CD3+ CTL mediate 
MHC-unrestricted killing of target cells in vitro (133). Unlike NK cells, 
these TCRyo+/CD3+ CTL do require prior activation to display MHC-unrestricted 
CTX (134-136). Although not proven yet, the structure of the TCRyo receptors 
predicts antigen specificity and MHC restriction (for a review see 10). 
1.10 Introduction to the experimental work 
An important objective in tumor immunology is to develop effective 
immunotherapy for cancer patients by means of BRM, either naturally present or 
artificically administered. In order to achieve this goal, fundamental and 
practical questions need to be answered. Some strategic questions are why do 
transformed cells develop into tumors when there is an adaptive and natural 
immune response to destroy them? Is the immune system deficient? If not, are 
tumor cells non-immunogenic or do they lack expression of antigenic 
determinants? Do tumor cells activate mechanisms of immunosuppression? Answers 
to these questions will allow to modulate and mobilize the host immune system 
in a controlled way so that efficient reduction or even elimination of the 
tumor is achieved. 
The purpose of the studies described in this thesis was to increase the 
insight in the potential usefulness of cytotoxic lymphocytes as antitumor 
agents. First, we studied the involvement of TCRa~+/CD3+ and TCRyo+/CD3+ CTL 
and TCR-/CD3 NK cells in tumor cell lysis and the regulation of their lytic 
functions by other T-cell subsets (137,138, chapter 2 and 3 of this thesis). 
Next, we investigated which strategy was most efficient to reduce or eliminate 
tumor cells by using cytotoxic lymphocytes such as TCR-/CD3- NK cells or 
TCRa~+/CD3 CTL. 
Although in the last few years much has been learned about TCR 
recognition of foreign antigens in association with MHC determinants on 
cultured tumor cell lines (see section 1.3), little is known about recognition 
of fresh tumor cells in vivo by CTL and NK cells. To use T and NK cells for 
immunotherapeutic aims, detailed studies into 
tumor cells can be recognized and killed are 
the mechanisms by which fresh 
necessary. Therefore, the 
availability of large numbers of functionally stable T and NK cells is a 
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prerequisite. Unfortunately, the growth capacity ofT and NK cells in tissue 
culture systems is limited and requires the presence of feeder cells, lectins, 
IL-2 and other unknown growth factors. The establishment of immortalized T and 
NK cells is therefore of paramount importance. Immortalization by somatic cell 
hybridization seemed to be a promising method to obtain permanent cytotoxic 
cell lines. This technique has proven to be successful in immortalizing mouse 
B lymphocytes for the production of mAb (139). Although less successful, 
hybridoma technology has also been used for immortalization of human B cells 
and human T cells which produce growth factors (140-143). However, 
immortalization of the lytic function of lymphocytes by hybridoma technology 
has been proven to be extremely difficult. This could be due to nonspecific 
lysis of the tumor fusion partner by the cytotoxic lymphocytes during or after 
the fusion procedure (144). Moreover, the production of human-human hybridomas 
in general is difficult, due to (1) the slow establishment of initial growth 
of fusion products (145, 146) and (2) chromosomal instability (147). Thus far, 
hybridoma cell lines with cytolytic activity have been d~scribed only in the 
mouse-mouse and mouse-human system (148-150). 
In view of these problems we first developed a new technique for the 
efficient production of human-human T-T cell hybridomas (151,152). This 
protocol, described in chapter 4, is based on the electric field-induced cell 
fusion used by Zimmermann (153) for plant cell fusions. Using this approach it 
was possible to efficiently produce human-human T-cell hybridomas. However, 
the few hybridomas that were cytolytic lost this activity within a short 
period of time. On the basis of the large number of hybridomas tested (more 
than 500) we concluded that immortalization of cytotoxic lymphocytes by 
somatic cell hybridization is not feasible (chapter 4 of this thesis). 
DNA-mediated gene transfer is an alternative approach. In this respect it is 
important to identify the genes involved in proliferation. Chapter 5 describes 
the expression of oncogenes and growth factors in normal and malignant 
TCR~~+/CD3+ and TCR-/CD3- lymphocytes. The expression of the c-myc and e-ras 
oncogene as well as IL-2R levels has been studied on the mRNA and protein 
level, respectively. To screen large numbers of T and NK-cell clones on the 
expression of the different oncogenes, we (88) modified the "quick blot" 
technique developed by Bresser et al. (154). This technique only requires low 
cell numbers and experiments can be performed in a short time. IL-2R levels 
have been measured using anti-CD25 mAb. 
In the future, immortalized cytotoxic lymphocytes may be used for 
immunotherapeutic aims. The other approach to eliminate or reduce tumor cells 
is to modulate the lytic function of cytotoxic lymphocytes by application of 
BRM. Chapter 6 describes the enhancement of the CTX of TCR-/CD3- NK cells and 
TCR~~+/CD3+ CTL by the BRM IL-2 and OK-432, using cloned lymphocytes. We 
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identified which lymphocyte cell types are suitable to use for therapeutic 
aims when treated with BRM (155). 
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CHAPTER 2 
LYTIC ACTIVITY OF TCRyo+/CD3+ CYTOTOXIC T-CELL CLONES AGAINST 
FRESH AND CULTURED TUMOR CELLS 
2.1 Introduction 
Tumors induced in experimental animals by carcinogens or by viruses 
often express tumor-associated antigens (TAA) which can activate the immune 
system in the host (156,157). In contrast, most "spontaneous" tumors are 
non-immunogenic, i.e. do not provoke an immune response (3,157). TCRa~+/CD3+ 
cytotoxic T lymphocytes (CTL) recognize and lyse immunogenic tumor cells 
expressing TAA in the context of major histocompatibility complex (MHC) 
determinants (adaptive immunity), whereas TCR-/CD3 natural killer (NK) cells 
recognize and lyse also non-immunogenic tumor cells (natural immunity) (158). 
Recently, a third subset of cytotoxic lymphocytes, termed TCRyo+/CD3+ 
CTL, has been cloned from peripheral blood lymphocytes (PBL) (134) and from 
immunodeficiency patients (159). TCRyo+/CD3+ CTL share several features with 
TCR-/CD3 NK cells as well as with "classic" TCRa~+/CD3+ CTL. Like TCR-/CD3 
NK cells, most TCRyo+/CD3+ CTL are CD4- and cos- and are CD16+, although this 
latter receptor is readily lost during in vitro culture (134). TCRyo+/CD3+ 
CTL, upon activation, also exert MHC-unrestricted cellular cytotoxicity (CTX) 
(21,22,134-136). The TCRyo protein chains are distinct in composition from the 
TCRtt~ but similarly noncovalently linked to the CD3 complex (23,24,160). The 
TCRyO structure may be involved in specific interactions (136,160). 
Recently, results from others and ourselves have shown that TCRyo+/CD3+ 
CTL kill cultured tumor cells (23,134,162). In this study we compared the 
lytic capacity of cloned TCRyo+/CD3+ CTL with that of cloned TCRa~+/CD3+ CTL 
and TCR-/CD3 NK cells using a variety of fresh and cultured tumor target 
cells. 
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2.2 Materials and methods 
2.2.1 Cells and cell culture 
Cloned lymphocytes studied are listed in Table 2.1. They were cultured 
as described previously (163). Briefly, responder cells (2x103 cells/200 ~1) 
were expanded in RPMI medium supplemented with 10% human serum (not 
heat-inactived), 4 mM glutamin, 1 ~g/ml indomethacin, 25 U/ml recombinant 
interleukin-2 (IL-2) and antibiotics. Gamma-irradiated (20 Gy) B-LCL (Sx10 4 
cells/200 ~1) and y-irradiated (20 Gy) allogeneic lymphocytes (10 5 cells/200 
~1) were added as feeder cells. 
TABLE 2.1 
CHARACTERISTICS OF HUMAN CLONED CYTOTOXIC LYMPHOCYTES 
clones CD3 CD4 CD8 CD16 TCR derived from ref. 
CTL4 + + PBL healthy donor 134 
CTL119 + + pleura exudate 134 
CTL1005 + + CD4-coa- enriched fraction 134 
CTL1011 + + co4-cos- enriched fraction 134 
CTL1012 + + co4-coa- enriched fraction 134 
CTL1015 + + CD4-CD8- enriched fraction 134 
CTLWi-K + liquor 134 
NK76 + PBL Ty lymphocytosis 163 
NK77 + PBL Ty lymphocytosis 163 
NK472 + PBL SCID 163 
CTLll + + PBL healthy donor 166 
CTL20 + + PBL healthy donor 167 
SCID severe combined immunodeficiency disease 
TCR T-cel receptor 
2.2.2 Target cells 
Fresh tumor cells. Tumor cells were isolated from pleura or ascites of cancer 
patients with ovarian, mammary, lung, endometrium and one mesothelioma 
carcinoma (Table 2.2). To separate tumor cells from exudate lymphocytes in 
pleura or ascites, cells were centrifuged on a Ficoll-gradient with 2 
densities (d=1.077 g/cm and d=0.8078 g/cm). The low density cell fraction 
contains the tumor cells and the high density cell fraction the lymphocytes. 
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The latter were not used in these experiments. Tumor cells isolated from 
pleura or ascites, were identified by microscopic analysis of smears stained 
with May Grlinwald-Giemsa. Contamination of the low density fraction with 
lymphocytes, detected by using anti-CD3 monoclonal antibodies (mAb), was less 
than 2%. In most of the preparations contamination of the tumor cell fraction 
with low percentages of macrophages was observed. Tumor cells were frozen and 
stored in liquid nitrogen. After thawing, dead cells were removed by 
Ficoll-Isopaque (d=0.8078 g/cm) and viability of the cells was measured by 
trypan blue staining. 
TABLE 2.2 
CHARACTERISTICS OF FRESH TUMOR CELLS 
type of tumor 
lung1685 
endometriuml689 
endometrium1784* 
ovarian1690 
ovarian1762 
ovarian1781 
mammary1721 
mammary1806 
mesothelioma1791 
isolated from 
pleura 
ascites 
ascites 
ascites 
ascites 
ascites 
ascites 
pleura 
aci tes 
* including sarcoma components 
malignancy 
pap V 
pap V 
pap V 
pap V 
pap V 
pap V 
pap V 
pap V 
pap V 
pap V = malignant cells were found in pleura or ascites 
Cultured tumor cells. Tumor cell lines used as targets in the CTX tests are 
listed in Table 2.3. Tumor cell lines were cultured in RPMI-medium 
supplemented with 10% fetal calf serum (FCS; heat-inactivated), 2 mM glutamin 
and antibiotics. 
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TABLE 2.3 
CHARACTERISTICS OF CULTURED TUMOR CELLS 
tumor cell line 
K562 
MOLT 
HSB 
JURKAT 
DAUDI 
APD 
BSM 
LICRON-HMY-2 
GLC1 
GLC2 
GLC3 
IGR137* 
IGR139* 
SKMEL* 
OMEL* 
T24 
U937 
Human origin 
myeloid cells 
T-lymphoma 
T-lymphoma 
T-lymphoma 
EBV-transf B cells 
EBV-transf B cells 
EBV-transf B cells 
B-cells 
small lung carcinoma 
small lung carcinoma 
small lung carcinoma 
melanoma cells 
melanoma cells 
melanoma cells 
melanoma cells 
bladder carcinoma 
cells 
monocytic cells 
source 
Cannon, Litton Bionetics 
Kensington, USA. 
Hagemeyer, Erasmus Univ. 
The Netherlands. 
Foung, Stanford Univ. 
Stanford, U.S.A. 
Foung, Stanford Univ. 
Stanford, U.S.A. 
de Vries, NKI, Amsterdam 
The Netherlands. 
Giphart, Leiden, 
The Netherlands. 
Giphart, Leiden, 
The Netherlands. 
Croce, Wistar 
Institute, U.S.A. 
de Ley, RUG, Groningen, 
The Netherlands. 
de Ley, RUG, Groningen, 
The Netherlands. 
de Ley, RUG, Groningen, 
The Netherlands. 
de Vries, Amsterdam, 
The Netherlands. 
de Vries, NKI Amsterdam 
The Netherlands. 
de Ley, RUG, Groningen, 
The Netherlands. 
de Vries, NKI, Amsterdam 
The Netherlands. 
Perlman, Wenner-Gren 
Institute, Stockholm 
Roozemond, AMC 
Amsterdam, the Netherlands 
* melanoma cells were cultured for a few passages 
2.2.4 Determination of cytotoxic activity 
CTX was determined in a 51 Cr-release assay in round-bottom microtiter 
plates, as described previously (164). Briefly, varying cell numbers in 150 ~1 
RPMI-medium, supplemented with 10% FCS (heat-inactivated), 2 mM glutamin and 
antibiotics, were seeded in the wells of the microtiter plate before the 
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addition of 2x10 3 51 Cr-labeled target cells (100 ~1). Cells were incubated for 
3 h at 37°C and centrifuged. Supernatant (100 ~l) was collected and 
radioactivity determined. Specific 51 Cr-release was calculated as: 
experimental cpm - spontaneous cpm 
X 100% 
maximum cpm - spontaneous cpm 
The maximum 51 Cr-release was obtained by incubation of the target cells with 
10% (v/v) Triton X-100. 
2.3 Results 
Lysis of fresh tumor cells 
We have tested in 3 separate experiments the CTX of 6 TCRyo+/CD3+ CTL 
clones, 2 TCR-/CD3- NK and 2 TCR~~-/CD3- CTL clones against fresh tumor cells 
from different histological type. All TCRyo+/CD3+ CTL, TCR-/CD3-NK and 
TCR~~+/CD3+ CTL clones expressed CTX against at least some of the fresh tumor 
cells used. The results of a representative experiment are provided in Table 
2.4. In the 3 experiments the level of CTX by TCRyo+/CD3+ was virtually as 
high as that of TCR-/CD3 NK cells, and in some cases higher (endometrium 1784 
and ovarian 1690). Clear differences were observed in lysis of different 
tumors. For instance, mammary carcinoma 1721 was not susceptible to lysis but 
mammary carcinoma 1806 was lysed by both cloned TCRyo+/CD3+ CTL and TCR-/CD3 
NK cells. Ovarian carcinomas 1762 and 1781 were both lysed by TCRyo+/CD3+ CTL 
and TCR-/CD3- NK clones, and the latter also by TCR-/CD3 NK clones. Moreover, 
both tumor targets were also lysed by the TCR~~+/CD3+ CTL clones CTL11 and 
CTL20, whereas ovarian carcinoma 1690 was only lysed by TCRyo+/CD3+ CTL 
clones. Endometrium carcinoma 1689 was efficiently lysed by clones of all 
lineages, but endometrium carcinoma 1784 was only susceptible to lysis by 
TCRyo+/CD3+ CTL clones. Mesothelioma 1791 was lysed by some of the TCRyo+/CD3+ 
T-cell and TCR-/CD3- NK clones but not by TCR~~+/CD3+ CTL clones. Lung tumor 
cells were not lysed by any of the clones. 
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TABLE 2.4 
LYSIS OF FRESH TUMOR CELLS BY DIFFERENT EFFECTOR CELLS 
tumor effector 
target cells cell clones 
TCRyo+ /CD3+ TCR-/CD3- TRC~~+/CD3+ 
CTL4 CTL1005 CTL1011 CTL1012 CTL1015 AKWi-K NK76 NK77 CTL11 CTL20 
percent lysis of target cells* 
lung1685 3 nt 0 nt 5 7 nt nt 6 1 
endom1689 20 50 26 66 31 40 42 80 33 15 
endom1784 14 20 12 nt 20 20 5 9 9 10 
ovarian1690 5 10 10 nt 10 22 7 7 7 2 
ovarian1762 0 nt 6 nt 29 40 nt nt 16 61 
ovarian1781 10 24 17 15 32 29 14 22 10 11 
mammary1721 1 6 1 2 2 7 1 6 3 0 
mammary1806 10 26 6 14 17 22 9 27 4 5 
mesothe1791 1 12 2 1 3 15 8 12 6 3 
* Results expressed as percent 51 Cr-release; effector: target ratio 27:1 
Lysis of cultured tumor cells 
The clones described in the previous section, and 2 other clones (CTL119 
and NK472), were tested for their CTX against different tumor cell lines. All 
TCRyo+/CD3+, TCR~a+/CD3+ and TCR-/CD3- clones showed CTX against at· least some 
of the cultured tumor target cells used (Table 2.5). 
As found for "fresh" tumor cells, the levels of CTX of TCRyo+/CD3+ CTL 
and TCR-/CD3- NK clones against cultured tumor cells were comparable. K562 
tumor cells (MHC-) were lysed by cloned TCRyo+/CD3+ CTL and TCR-/CD3 NK 
cells, and by the TCRa~+/CD3+8+ clone CTL11, but not by the MHC class II 
specific TCRa~+/CD3+,4+ clone CTL20 (Table 2.5). T-lymphoma cells were lysed 
by TCRyo+/CD3+ CTL and TCR-/CD3- NK clones and (one tumor cell line (HSB) 
marginally), by the TCR~~+/CD3+ clone CTL11 (Table 2.5). 
B-lymphoma cells, which were efficiently lysed by cloned TRC-/CD3- NK 
cells, appeared resistent to TCRyo+/CD3+ CTL clones. Two exceptions were 
observed: clones CTL4 and CTL1005 efficiently lysed Daudi B~lymphoma cells 
(Table 2.5). 
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TABLE 2.5 
LYSIS OF CULTURED TUMOR CELLS BY DIFFERENT EFFECTOR CELLS 
percent lysis of tumor cells* 
effector 
cell clones erythroid T cells B cells 
K562 MOLT HSB JUR DAU APD BSM LICR 
TCRy&+ /CD3+ 
CTL4 46 51 33 18 59 13 9 0 
CTL119 56 53 39 33 0 5 0 0 
CTL1005 82 57 nt nt 63 3 3 16 
CTL1011 72 32 nt nt 3 0 0 5 
CTL1012 71 41 nt nt 0 3 3 0 
CTL1015 36 13 nt nt 0 0 0 2 
AKWi-k nt nt nt nt 0 0 0 nt 
TCR-/CD3-
NK76 57 50 nt 74 68 46 80 7 
NK77 66 65 nt 84 44 25 74 5 
NK472 58 35 nt 57 53 57 22 13 
TCRor.l3+ /CD3+ 
CTLll 65 0 18 0 0 0 62 77 
CTL20 1 0 nt nt 0 58 0 0 
* Results expressed as percent 51 Cr-release; effector:target ratio. 
The (Drw6) MHC class !!-specific TCRor.j3+/CD3+ clone CTL20 only lysed the 
relevant APD target cells (Drw6+). Lung tumor cells (GLC1-3) were lysed by 
both TCR-/CD3- NK and TCRy&+/CD3+ CTL clones, but not or only slightly by the 
TCRor.j3+/CD3+ clone CTL11 (Table 2.6). 
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TABLE 2.6 
LYSIS OF CULTURD TUMOR CELLS BY DIFFERENT EFFECTOR CELLS 
percent lysis of tumor cells* 
effector 
cell clones lung melanoma bladder mono 
GLC1 GLC2 GLC3 IGR37 IGR39 SKMEL OMEL T24 U937 
TCRy&+/CD3+ 
CTL4 56 15 16 31 9 24 8 23 29 
CTL119 41 22 18 21 8 9 46 39 1 
CTL1005 57 20 nt 56 nt 49 15 38 26 
CTL1011 24 3 nt 13 nt 21 11 15 13 
CTL1012 52 51 nt 66 nt 11 27 6 11 
CTL1014 42 47 nt 11 nt 68 47 93 20 
CTL1015 4 1 nt 3 nt 14 5 12 3 
CTLWi-K 32 35 nt 4 nt nt 24 nt nt 
TCR-/CD3 
NK77 62 40 40 8 0 16 67 30 82 
TCRcx13+ /CD3+ 
CTL11 12 0 0 8 0 30 70 0 0 
CTL20 nt nt nt 4 1 11 7 0 2 
* Results expressed as percent 51 Cr-release; effector:target ratio 27:1 
Most of 
TCRy&+/CD3+ CTL 
also lysed by 
the melanoma cells (IGR37, SKMEL and OMEL) were lysed by 
clones. However, SKMEL and OMEL, but not IGR37 and IGR39, were 
the TCR-/CD3- clone NK77 and TCRcxj3+/CD3+ clone CTLll. The 
bladder carcinoma T24 and the monocytic cell line U937 were efficiently lysed 
by TCRy&+/CD3+ CTL and TCR-/CD3- NK clones but not by the TCRcx13+/CD3+ clone 
CTLll. Except for APD, none of the tumor cell lines used were lysed by the MHC 
class II-restricted TCRcxj3+/CD3+ clone CTL20. 
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2.4 Discussion 
Thus far, little is known about the physiological function of 
TCRyo+/CD3+ CTL in the overall immune response. Although TCRyo+/CD3+ CTL have 
been implicated in the cytolysis of virus-infected target cells (132), we 
found no increased susceptibility of virus infected cells in vitro 
(unpublished data). Janeway et al. (161) have proposed that TCRyo+/CD3+ CTL 
may demonstrate specificity for class I MHC antigens and mediate immunological 
surveillance of epithelia. Since activated TCRyo+/CD3+ lymphocytes have also 
been isolated from the joint fluid of patients with juvenile rheumathoid 
arthritis (165), they may be involved in the pathogenic mechanisms of this 
disease. 
Experimental results (23,134) suggest that TCRyo+/CD3+ CTL may also be 
involved in antitumor 
TCRyo+/CD3+ CTL clones 
responses. In the present study we have compared 
with TCR-/CD3 NK and TCRtt~+/CD3+ CTL clones with 
respect to their CTX against different freshly biopsied as well as cultured 
tumor cells. Comparison of cloned TCRyo+/CD3+ CTL with cloned TCR-/CD3 NK and 
TCRtt~+/CD3+ CTL showed that the CTX of activated cloned TCRyo+/CD3+ CTL 
against fresh tumor cells was comparable to that of TCR-/CD3- NK clones. Our 
data indicate that TCRtt~+/CD3+ antitumor CTX is generally lower than that of 
TCRyo+/CD3+ clones. With respect to cultured tumor cells, the target cell 
spectrum of TCRyo+/CD3+ clones was virtually as wide as that of TCR-/CD3 NK 
cells. However, an exception was observed for B-tumor cells, i.e. 
EBV-transformed B cells (APD, BSM and Daudi) and a leukemia plasma cell line 
(Licr), which in general were efficiently lysed by cloned TCR-/CD3 NK cells, 
were not lysed by cloned TCRyo+/CD3+ CTL. Why this TCRyo+/CD3+ clones do not 
kill B tumor cells remains to be elucidated. 
Different fresh and cultured tumor target cells show differential 
susceptibility to lysis by an individual effector clone (Tables 2.4, 2.5 and 
2.6). Also different cultured tumor cells of the same histological type showed 
differential lysability by TCRyo+/CD3+ clones and TCR-/CD3- NK cell clones. 
Vice versa, individual effector clones showed particular target cell spectra, 
i.e. lysed different tumor cells with different efficacies. How can these 
differences be explained? A large body of data show that CTX can be inhibited 
by mAb directed against effector cell surface molecules which were not 
directly involved in antigen recognition, i.e. non-TCR structures. Furthermore 
the heterogeneity of recognition by the cloned effector cells may be explained 
by differences in the (level) of expression and/or nature of (a) MHC 
determinants, (b) TAA and (c) tumor cell ligands for effector cell accessory 
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molecules, such as ICAM-1 and LFA-3. 
An additional level of complexicity results from synergistic 
activations between distinct activation sites such as CD2 and CD16, CD2 and 
CD3, suggesting that (intracellularly) the activation sites converge (27). 
Therefore, the target cell selectivity of a particular (cloned) lymphocyte may 
critically be determined by the relative expressions of these structures on 
effector as well as on tumor target cells and their interplay. 
35 
CHAPTER 3 
IN VITRO AND IN VIVO ACTIVATION OF CD4+ LYMPHOCYTES 
BY AUTOLOGOUS TUMOR CELLS 
3.1 Introduction 
Tumor cells can escape destruction by the host immune defense system in 
various ways. First, tumor cells can be non-immunogenic when they lack 
expression of major histocompatibility complex (MHC) or cognate antigens, and 
are thus incapable of provoking an immune response (157). Second, the host can 
be immunodeficient (168). Third, the tumor cells may induce immunosuppression 
mechanisms lowering or abrogating the activity of tumor directed cytotoxic T 
lymphocytes (CTL) (169). Evidence for this latter possibility was provided by 
Damle et al. (170,171) who showed that alloantigen-primed CD4+ (inducer) 
lymphocytes activate autologous cos+ cells to differentiate into suppressor 
cells that specifically inhibit the response of fresh T cells to the original 
allogeneic stimulator cells. Also Mukherji et al. (126,127) reported such a 
down regulatory mechanism generated by autologous tumor cells in man. These 
investigators used CD4+ (inducer) lymph node lymphocytes, derived from a 
patient with melanoma, which prevented the generation of a CTL-response 
against the melanoma cells, when added to a mixture of fresh peripheral blood 
lymphocytes (PBL) (containing pre-CTL) and autologous tumor cells. 
Thus far, most of the autotumor-directed TCRa~+/CD3+ CTL reponses have 
been observed against melanoma cells (126,127,172-176), but a few have been 
reported against larynx and bladder carcinoma (177). Expression of antigens 
characteristic for a tumor cell type, termed tumor-associated antigens (TAA), 
depends on the origin of the tumor, i.e. chemically or virally induced tumors 
are more immunogenic than spontaneous tumors (3,178,179). The existence of 
specific antigens on spontaneous tumors remains uncertain. Reports published 
sofar, demonstrate the difficulty to develop specific CTL responses against 
tumor cells arisen spontaneously in vivo. It is not clear whether the number 
of tumor-directed TCRa~+/CD3+ CTL and/or the strength of their response to 
autologous tumor cells is insufficient. Therefore, it is of importance to test 
PBL of cancer patients for the presence of activated T cells and subsequently 
36 
assay them against autologous tumor cells. 
Here, we have immunophenotyped PBL of 22 cancer patients and 21 healthy 
individuals. Lymphocytes derived from 9 of the patients had an increased 
percentage of CD25+ lymphocytes. The CD25, i.e. interleukin-2 receptor (IL-2R) 
is an activation marker forT cells (51). This raised the possibility that the 
tumor cells had activated these lymphocytes in vivo, resulting in the 
induction of IL-2R. Indeed, fresh PBL from these cancer patients could be 
stimulated in vitro by autologous tumor cells, which led to a further increase 
of IL-2R+ lymphocytes. We present evidence that CD4+ lymphocytes are 
preferentially activated by autologous tumor cells in vitro and in vivo. 
3.2 Materials and methods 
3.2.1 Lymphocytes 
PBL were obtained from blood of healthy donors and patients by 
centrifugation on Ficoll-Isopaque (d=1.077g/cm). All cells were frozen and 
stored in liquid nitrogen before their use as responder in 
mixed-lymphocyte-tumor-culture (MLTC) assays. 
3.2.2 Fresh tumor cells 
Tumor cells were isolated from pleura or ascites of cancer patients 
with ovarian, mammary, lung, gall-bladder, mesothelioma, and endometrium 
carcinoma (Table 3.1). To separate tumor cells from pleura and/or from 
peritoneal exudate lymphocytes, cells were centrifuged on a Ficoll-gradient 
with 2 densities (d=1.077g/cm and d=0.8078g/cm). The low density cell fraction 
represents the tumor cells and the high density cell fraction the lymphocytes. 
The latter were not used here. Presence of the tumor cells, isolated from 
pleura or ascites was confirmed by microscopic analysis of May Grunwald-Giemsa 
stained cytospins. Lymphocyte contamination of the low density tumor fraction 
was assessed with fluorescein isothiocyanate (FITC)-labeled anti-CD3 
monoclonal antibodies (mAb) and was always less than 2%. Tumor cells were 
frozen and stored in liquid nitrogen. After thawing, dead cells were removed 
by Ficoll-Isopaque centrifugation (d=0.8078g/cm) and viability of the cells 
was measured by trypan blue staining. Tumor cells were used for stimulation of 
autologous PBL in a MLTC and as target cells in cytotoxicity assays. 
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TABLE 3.1 
CHARACTERISTICS OF CANCER PATIENTS 
isolated chemo percent 
)2atient carcinoma mali~n. from treatment CD25 
1685 lung pap V pleura no nd 
1689 endometrium pap V ascites yes 17 
1784 endometrium* pap V ascites no 12 
1690 ovarian pap V ascites no nd 
1747 ovarian pap V ascites no 29 
1754 ovarian pap V ascites yes 0 
1757 ovarian pap V pleura yes 10 
1762 ovarian pap V ascites yes nd 
1782 ovarian pap V ascites yes 7 
1790 ovarian pap v ascites yes 3 
1743 ovarian pap v ascites yes 22 
1798 ovarian pap v ascites yes 6 
1702 mammary pap v ascites yes nd 
1718 mammary pap III ascites yes 8 
1721 mammary pap v ascites yes 2 
1758 mammary pap v pleura no 14 
1783 mammary pap V pleura yes 0 
1789 mammary pap III pleura yes 22 
1806 mammary pap V pleura no 0 
1746 mesothelioma pap V ascites no 24 
1791 mesothelioma pap V ascites no 6 
1775 gall-bladder pap III ascites no 7 
1715 none pap II ascites yes 0 
1716 none pap I pleura no 6 
1759 none pap II ascites yes 11 
1767 none pap II ascites yes 11 
pap 1 and 2 = nonmalignant cells were found in pleura or ascites 
pap 3 = observed cells were suspected of malignancy 
pap 4 and 5 = malignant cells were found in pleura or ascites 
*including sarcoma components 
3.2.3 Cultured tumor cell line 
K562, a human erythroid cell line (provided by Dr. Grace Cannon, Litton 
Bionetics, USA) was used as natural killer (NK)-sensitive target cell line in 
cytotoxicity assays. Cells were cultured in RPMI supplemented with 10% fetal 
calf serum (FCS; heat-inactivated), 2 mM glutamin, and antibiotics. 
3.2.4 HLTC/14C-Thymidin incorporation/expansion 
The presence of MHC determinants on fresh tumor cells was tested by a 
allogeneic mixed-lymphocyte-tumor-culture (MLTC). Stimulation of PBL by 
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autologous tumor cells was examined in an autologous MLTC. MLTC assays were 
performed in 96-well round-bottom microtiter plates (Greiner). Responder cells 
(10 5 ) in 0.2 ml RPM!, containing 10% normal human serum (not 
heat-inactivated), 4 mM glutamin and antibiotics, were mixed with 2x104 
y-irradiated (25 Gy) allogeneic or autologous tumor cells and cultured for 1 
week. To measure stimulation of PBL by allogeneic or autologous tumor cells, 
lymphocytes in triplicate wells were pulsed with 14 C-Thymidin and 18 h later 
harvested on glass fiber filters. To select for autotumor-reactive T cells, 
MLTC-derived cells (from autologous combinations) were cultured with 25 U 
recombinant IL-2/ml (Biogen, Geneva, Switzerland) ~or 1 week and expanded in a 
T-cell culture system described earlier (33). Briefly, responder cells (2x10 3 
cells/well) were cultured in 200 ~l RPM! medium supplemented with 10% human 
serum (not heat-inactivated), 4 mM glutamin, 1 ~g indomethacin/ml, 1 ~g 
leucoagglutinin/ml, 25 U recombinant IL-2/ml and antibiotics. Gamma-irradiated 
(20 Gy) Epstein-Barr virus-transformed human lymphoblastoid B-cell lines 
(B-LCL) (5x10 4 cells/200 ~l) and allogeneic lymphocytes (10 5 cell/200 ~l) were 
added as feeder cells. Feeder cells and medium weekly were refreshed. In each 
well 103 MLTC-derived lymphocytes were seeded. These MLTC-derived lymphocytes 
were expanded for 4 weeks, after which they were immunophenotyped and used as 
effector cells in cytotoxicity assays. 
3.2.5 Determination of cytotoxic activity 
CTX was determined in a 51 Cr-release assay in round-bottom microtiter 
plates (Greiner) as described earlier (164). Briefly, various numbers of cells 
in 150 ~l RPM! medium supplemented with 10% FCS (heat-inactivated), 2 mM 
glutamin and antibiotics, were seeded in the wells of the microtiter plate 
before addition of 2500-5000 51 Cr-labelled target cells (in 100 ~1). 
Cells were incubated for 3 h at 37°C and centrifuged. Supernatant (100~1) was 
collected and radioactivity was determined. 
calculated as follows: 
Specific 51 Cr-release was 
experiment cpm - spontaneous cpm 
X 100% 
maximum cpm - spontaneous cpm 
The maximum 51 Cr-release was obtained by incubation of the target cells 
with 10% (v/v) Triton X-100. 
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3.2.6 Phenotypic analysis and separation of lymphocyte subsets 
MAb used for phenotyping the lymphocytes and tumor cells are listed in 
Table 3.2. 
TABLE 3.2 
MONOCLONAL ANTIBODIES 
antigen dilution/amount 
mAb recognized used obtained from 
OKT3 CD3 1/4 Ortho Pharmaceuticals, 
culture sup. N.J. Raritan. 
OKT4 CD4 1/10 Ortho Pharmaceuticals, 
culture sup. N.J. Raritan. 
OKT8 CDS 1/4 Ortho Pharmaceuticals 
culture sup. N.J. Raritan. 
VD2 CD16 1/500 Central Laboratory Red 
ascites Cross The Netherlands. 
TAC CD25 1/1000 T. Uchiyama, Kyoto, 
ascites Japan. 
MHC Class I HLA-A,B,C 1/100 Seralab, Uden, 
culture sup. The Netherlands. 
MHC Class II HLA-Dr 1/1000 M. Jonker, TNO, 
culture sup. The Netherlands. 
Cells (2x105 ) were incubated for 30 min with the mAb, washed with 
phosphate-buffered saline supplemented with bovine-serum albumin, and 
incubated for 30 min with 40-fold diluted fluorescence 
isothiocyanaat conjugated (FITC) goat-anti mouse IgG (Nordic Tilburg, The 
Netherlands). Cells were washed again and analysed using a fluorescent 
activated cell sorter (FACS IV, Becton & Dickinson). Tumor cells were analysed 
by light microscopy. To separate CD4+ from CDS+ lymphocytes, fresh PBL were 
labeled with anti-CD4 and anti-COB mAb and separated on the FACS. To eliminate 
possible influences of anti-CD4 and anti-COS mAb on the proliferation of the 
lymphocytes, the CD4- fraction was used for experiments to analyse cos+ cells 
and vice versa. The IL-2R+ lymphocytes were separated from the IL-2R-
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lymphocytes by FACS using FITC anti-TAC mAb. In this case it was not possible 
to use the negative selection procedure and thus IL-2R+ fractions were used. 
3.3 Results 
3.3.1 14C-Thymidine incorporation 
Stimulation of PBL with autologous tumor cells (1690, 1702, 1718, 1721, 
1743, 1754, 1762 and 1784) in MLTC did not result in increased 14 C-Thymidine 
incorporations (Table 3.3). 
PBL 
1690 
1702 
1718 
1721 
1743 
1754 
1762 
1784 
HD1701 
HD1701 
HD1701 
HD1707 
HD1707 
HD1707 
HD1708 
HD1708 
HD1708 
TABLE 3.3 
14 C-THYMIDINE INCORPORATION IN PBL AFTER 
AUTOLOGOUS AND ALLOGENEIC MLTC 
carcinoma 
ovarian 
mammary 
mammary 
mammary 
ovarian 
ovarian 
ovarian 
endometrium* 
ovarianl689 
ovarianl690 
mammaryl702 
ovarianl689 
ovarianl690 
mammaryl702 
ovarian1689 
ovarian1690 
mammary1702 
autologous tumor cells 
+ 
(cpm) (cpm) 
410 320 
415 325 
422 616 
200 185 
353 685 
215 655 
290 390 
445 395 
allogeneic tumor cells 
+ 
(cpm) (cpm) 
1320 1640 
925 5760 
605 4705 
740 1765 
1060 5120 
995 1170 
815 1965 
815 5770 
1150 1740 
HD = healthy donor 
*including sarcoma components 
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Significant enhancement of 14 C-Thymidin incorporation was found in PBL 
of healthy donors when stimulated with fresh allogeneic tumor cells. 
3.3.2 Levels of IL-2R+ cells 
Fresh PBL of 22 patients and 
using mAb against CD3,4,8,16 and 25. 
it appeared that in 9 (1689, 1743, 
21 healthy individuals were phenotyped 
With respect to the IL-2 R+ (CD25) cells, 
1746, 1747, 1758, 1759, 1767, 1784 and 
1789) out of 22 patients their percentages were augmented varying between 11 
and 29% (Table 3.4). 
TABLE 3.4 
PHENOTYPE OF FRESH PBL OF CANCER PATIENTS 
percentage of positive cells 
patient carcinoma CD3 CD4 CDS CD16 CD25 
1689 endometrium 70 43 25 18 17 
1784 endometrium* nt 36 18 11 12 
1743 ovarian 61 35 41 22 22 
1746 ovarian 64 54 30 28 24 
1747 ovarian 62 49 24 14 29 
1754 ovarian 56 47 15 6 0 
1757 ovarian 77 62 9 3 10 
1782 ovarian 70 53 27 4 7 
1790 ovarian 70 42 23 9 3 
1798 ovarian 85 65 18 0 6 
1718 mammary 51 43 11 13 8 
1721 mammary 11 5 0 15 2 
1758 mammary 57 37 14 10 14 
1783 mammary 68 46 24 11 0 
1789 mammary 74 53 20 9 22 
1806 mammary 57 33 17 8 0 
1775 gall-bladder 46 26 39 27 7 
1791 mesothelioma 80 39 35 4 6 
1759 none 60 53 10 3 11 
1767 none 64 56 15 5 11 
1715 none 72 65 7 0 0 
1716 none 60 22 34 6 6 
healthy individuals (n=21) 0-10 
*including sarcoma components 
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From patie~t 16S9 the IL-2R+ and IL-2R- cells were fractionated and 
immunophenotyped again. The IL-2R+ fraction predominantly 
lymphocytes and CD3- NK cells, while the IL-2R- fraction 
lymphocytes (Table 3.5). 
TABLE 3.5 
contained CD4+ 
comprised cos+ 
CELLULAR COMPOSITION OF IL-2 RECEPTOR POSITIVE AND NEGATIVE FRACTION 
OF PATIENT 16S9 
percent of positive cells 
days of IL-2R 
culture fraction CD3 CD4 CDS CD16 CD25 
0 unfractionated 70 43 25 1S 17 
14 6S 11 69 s nt 
14 + nt 22 23 27 nt 
3.3.3 Cytotoxic activity 
From 10 patients (16S5, 16S9, 1690, 1702, 1721, 1743, 1754, 1762, 17S4 
and 1S06) PBL were stimulated with autologous tumor cells in MLTC, cultured 
with recombinant IL-2 and expanded during two weeks. Cellular CTX of these 
MLTC-derived cells was tested against autologous and allogeneic fresh tumor 
cells as well as against K562 tumor cells (Table 3.6). In 5 out of 10 cases 
(16S5, 16S9! 1690, 1762 and 17S4) fresh tumor cells were killed by 
MLTC-derived autologous lymphocytes; 4 out of these 5 (16S9, 1690, 1762 and 
17S4) also lysed K562. In 1 case, only K562 tumor cells were killed. In 2 out 
of 5 cases autologous tumor cells but also allogeneic fresh tumor cells were 
lysed (PBL1690 and PBL1762) by MLTC-activated lymphocytes. 
43 
.TABLE 3.6 
CTX OF MLTC-DERIVED PBL FOR FRESH AUTOLOGOUS, FRESH ALLOGENEIC 
AND CULTURED K562 TUMOR CELLS 
percent lysis of target cells* 
PBL** cultured fresh tumor cells 
Patient K562 .,..1.,..,68_,5,.---,-1.,..,68"'9........,.1""'6 9"'0........,.1"""7 0"'2~1.;o,72""'1~1~7 4.,_,3~1.;o,7 5;,;-;4;.--,.1""'7 6"2;--::-1""'7 8"4...--::-1""8=06 
1685 9 20 4 
1689 16 13 5 
1690 35 23 17 
1702 7 
1721 9 0 0 1 
1743 9 0 0 
1754 4 1 0 0 
1762 19 11 12 
1784 65 9 15 
1806 35 8 
* Results are expressed as percent 51 Cr-release; 
effector:target ratio 27:1; >10% of lysis is considered as 
relevant; 
** PBL were derived from autologous MLTC 
To test whether the observed autologous tumor cell lysis was 
tumor-selective PBL of patient 1689 were expanded without prior MLTC; the 
lysis of autologous tumor cells and K562 cells was 22% and 21%, respectively. 
However, MLTC-derived lymphocytes (autologous combination) showed 13% and 16% 
lysis of autologous and K562 tumor cells, respectively. Moreover, when PBL of 
patient 1689 were expanded without PHA in the culture system, the level of 
autologous tumor cell lysis was only 2% (Table 3.7). In this experiment we 
also tested the CTX of a TCR~~+/CD3+ and a TCR-/CD3- NK-cell clone against 
tumor 1689. Both types of clones showed high CTX, i.e. 44 and 43% lysis of 
fresh tumor cells, respectively, and 65 and 54 % lysis of K562 tumor cells, 
respectively (Table 3.7). Furthermore, PBL of a healthy individual incubated 
either with or without tumor cells of patient 1689 and expanded in the 
presence of PHA showed 23 and 27% lysis of this tumor. 
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TABLE 3.7 
CTX OF DIFFERENT EFFECTOR CELLS AGAINST FRESH AUTOLOGOUS 
AND K562 TUMOR CELLS 
percentage lysis of target cells* 
tumor tumor 
effectors 1689 1689 
HD 23 
HD + 27 
NK76 44 
CTLll 43 
1689/PBL-lect 2 
1689/PBL+lect** + 13 
1689/PBL+lect 22 
* Results expressed as percent 51 Cr-release; 
effector:target ratio 27:1 
** Results were obtained from another experiment 
HD = healthy donor 
K562 
tumor cells 
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43 
65 
54 
3 
16 
21 
3.3.4 Influence of tumor cells on the cellular composition of autologous PBL 
The in vitro influence of tumor cells on the cellular composition of 
autologous PBL of 4 patients was tested by phenotypic analysis with 
anti-CD3,4,8,16 and 25 mAb. The PBL were stimulated in a MLTC, cultured with 
recombinant IL-2 and expanded during 4 weeks. 
Patient 1718 
After 2 weeks of expansion of MLTC/IL-2 derived lymphocytes a decrease 
in the number of CD16+ lymphocytes and a slight increase in the number of CD3+ 
and CD4+ lymphocytes was observed (Table 3.8). 
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TABLE 3.S 
THE IN VITRO ACTIVATION OF CD4+ LYMPHOCYTES BY AUTOLOGOUS TUMOR CELLS 
patient 
171S 
1721 
1743 
1S06 
171S 
171S 
1721 
1721 
1743 
1743 
1S06 
1S06 
(PBL were used as responder cells in the MLTC) 
fresh PBL 
tumor cells percent of positive cells 
CD3 CD4 CDS CD16 CD25 
51 43 11 13 s 
11 5 0 15 nd 
61 35 41 22 22 
57 33 17 s 0 
MLTC/IL-2 derived cells after 2 weeks of expansion 
absolute number of positive cells* x 103 
CD3 CD4 CDS CD16 CD25 
126.7 106.4 35.5 141.9 167.2 
+ 200.1 190.0 2.5 5.1 195.0 
336.0 336.0 33.6 0.0 26S.S 
+ 442.0 442.0 0.0 0.0 243.7 
215.S 137 .s 96.2 o.o 215.S 
+ 340.0 300.0 124.0 0.0 316.0 
617.2 379.9 251.S 113.7 592.S 
+ S93.1 571.2 332.3 62.3 S20.4 
* absolute numbers of positive cells were calculated by: initial 
number of cells per well x percent positive cells x multiplification 
factor after one week of culture. 
After 4 weeks, a strong increase of CD3+, CD4+ and CD25+ cells but no 
change in the number of ens+ cells was found (Table 3.9). 
Patient 1721. 
For this patient only a slight stimulatory influence of the tumor 
cells on the cellular composition of autologous PBL was found. An increase in 
the number of CD3+, CD4+ and CD25+ cells after stimulation with the tumor 
cells, could only be observed after 2 weeks of expansion of MLTC/IL-2 derived 
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lymphocytes (Table 3.S). Low numbers of CDS+ cells were present in fresh PBL 
but tumor cells could not induce activation. The CD16+ lymphocytes were no 
longer detected after MLTC and 4 weeks of expansion (Table 3.9). 
TABLE 3.9 
THE IN VITRO ACTIVATION OF CD4+ LYMPHOCYTES BY AUTOLOGOUS TUMOR CELLS 
(PBL were used as responder cells in the MLTC) 
fresh PBL 
patient tumor cells percent of positive cells 
CD3 CD4 CDS CD16 CD25 
171S 51 43 11 13 s 
1721 11 5 0 15 nd 
1743 61 35 41 22 22 
1S06 57 33 17 s 0 
MLTC/IL-2 derived cells after 4 weeks of expansion 
absolute number of positive cells* x 103 
CD3 CD4 CDS CD16 CD25 
171S 123.5 39.0 136.5 152.S 39.0 
171S + 560.6 414.4 26S.l 146.3 349.4 
1721 739.5 714.0 51.0 0.0 493.0 
1721 + 494.5 440.9 53.6 0.0 26S.l 
1743 610.0 291.0 465.5 0.0 31S.9 
1743 + 401.4 233.4 275.3 9.3 242.7 
1S06 36.7 1S.6 14.7 0.0 21.6 
1S06 + 79.0 lS.O 33.0 4.0 30.0 
* absolute numbers of positive cells were calculated by: initial 
number of cells per well X percent of positive cells 
x multiplification factor after one week of culture. 
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Patient 1743 
For this patient, an increase in the number 
cells was observed after 2 weeks of expansion of 
of CD3+, CD4+ and CD25+ 
the MLTC/IL-2 derived 
lymphocytes (Table 3.S), while CDS+ cells responded weakly to autologous tumor 
cells. After 4 weeks the number of CD4+ and CDS+ as well as CD25+ cells were 
decreased (Table 3.9). 
Patient 1S06 
After 2 weeks of expansion of the MLTC/IL-2 
strong increase was observed in the number of CD3+ 
cells and a much smaller increase in the number of 
derived lymphocytes, a 
and CD4+ as well as CD25+ 
CDS+ cells (Table 3.S). 
After 4 weeks of expansion, no further influence of the tumor cells on 
autologous lymphocytes could be detected i.e. differences in the number of 
CD3+, CD4+, CDS+, CD16+ or CD25+ were not observed when cultured either with 
or without tumor cells (Table 3.9). 
3.3.5 Influence of tumor cells on the proliferation of CD4- and cos-
fractions 
CDS lymphocyte fraction of patient 1S06 
After 2 weeks of expansion of the MLTC/IL-2 derived 
(CD4+-enriched) lymphocyte fraction, a strong increase in the number of 
CD4+ and CD25+ cells, but also in the number of CD16+ cells was found 
cos-
CD3+, 
(Table 
3.10). Expectedly, no cos+ lymphocytes were found. After 4 weeks of expansion, 
differences in the number of CD3+, CD4+, CD16+ and CD25+ lymphocytes could no 
longer be detected. 
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TABLE 3.10 
THE IN VITRO ACTIVAITON OF CD4+ LYMPHOCYTES BY AUTOLOGOUS TUMOR CELLS 
(CD4+-enriched lymphocytes were used as responder cells in the MLTC) 
day of culture tumor CD4+ enriched lymphocytes 
after MLTC/IL-2 cells Eercent of positive cells 
CD3 CD4 CDS CD16 CD25 
0** 5 33 17 s 0 
MLTC/IL-2 derived cells 
103 absolute number of positive cells*x 
14 1Sl.S 1755.0 23.4 140.4 1755.0 
14 + 266.4 2607.S 34.3 377.4 2642.1 
2S 57.2 49.6 o.s 9.6 
2S + 94.9 SS.4 0.0 6.5 
* absolute numbers of positive cells were calculated by: 
initial number of cells per well x percent positive cells 
x multiplification after one week of culture 
** unfractionated 
CDLf- lymEhocyte fraction of patient 1S06 
34.4 
61.1 
No proliferation of MLTC-derived CD4--fractionated lymphocytes (i.e. 
cos+ lymphocytes) was obtained. 
3.4 Discussion 
In the first part of this study we have shown that uncultured, i.e. 
fresh tumor cells derived from lung, ovarian, mammary and endometrium 
carcinomas could not induce tumor-reactive CTX in autologous PBL. Low levels 
of CTL by MLTC-derived PBL were found against autologous as well as allogeneic 
fresh tumor cells (Table 3.6). Limiting dilution of autotumor stimulated PBL 
did not yield clones with autotumor-directed cytotoxicity (data not shown). 
Phenotypic analysis of tumor cells revealed that MHC expression varied 
from 17-83% for class I and from 26-82% for class II antigens (tumor 1689, 
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1721, 1743 and 1S06). Tumors 16S9, 1690 and 1702 induced high 14 C-thymidin 
incorporation in allogeneic PBL when used for stimulation in a MLTC (Table 
3.3). This phenomenon functionally demonstrated the expression of MHC 
determinants on these tumor cells. Phenotyping of fresh PBL from cancer 
patients suggest that their "spontaneously" in vivo arisen tumor cells express 
aberrant antigens. Evidence for this are the augmented levels of IL-2R+ 
lymphocytes (11-29%) found for fresh PBL from 9 out of 22 cancer patients, 
while fresh PBL from healthy individuals comprised 0-10% IL-2R+ cells. 
Induction of IL-2R on PBL in vivo by chemotherapeutic reagents can be 
excluded, since no correlation exists between the presence of enhanced levels 
of IL-2R+ cells and chemotherapeutic treatment of the cancer patients (Table 
3.1). Moreover, PBL from most of the treated patients did not comprise 
enhanced levels of IL-2R+ cells. PBL of 2 patients showed 11% of IL-2R+ cells 
while malignant cells could not be detected in acites smears by microscopic 
analysis. However, in these cases the presence of malignant tumor cells in the 
body cannot be ruled out. In this respect, the use of primary tumors and/or 
metastases for experiments is more reliable, but other problems such as less 
viable tumor cells after enzymatic or mechanic treatment and possible 
subsequent destruction of foreign antigens favours the use of tumor cells from 
pleura and ascites. 
The question arises why enhanced numbers of IL-2R+ lymphocytes were 
found in PBL of only 9 out of 22 cancer patients. Unsuitable stimulation 
circumstances in vivo, i.e. optimal antigen/receptor interactions, 
insufficient IL-2 concentration as well as other factors, which can be 
optimized in vitro, may be an explanation for this failure. 
Separation and phenotypic analysis of the IL-2R+ and IL-2R- fresh PBL 
showed that CD4+ cells and CD16+ cells were mainly present in the IL-2R+ and 
CDS+ cells in the IL-2R- fraction. In vitro stimulation of PBL with autologous 
tumor cells in a MLTC showed a similar pattern. In all 4 cases CD4+ 
lymphocytes were stimulated by the tumor cells, as shown by enhanced 
proliferation as well as by an augmented level (absolute number) of IL-2R+ 
cells, although this occured with different strengths (patients 171S, 1721, 
1743 and 1S06) (Tables 3.S and 3.9). By contrast, cos+ lymphocytes were not 
stimulated at all, or at a much lower level than CD4+ lymphocytes. Similar 
results were observed for CD4+ and CDS+ enriched cell fractions (Table 3.10). 
These results suggest that CDS+ (cytotoxic/suppressor) lymphocytes may 
become inactivated in vitro or in vivo by autologous tumor cells. In the mouse 
system, it has been shown that soluble suppressor factors (Ts 1, 2 and 3) 
produced by each suppressor T cell subset may inhibit the CTL response against 
so 
autologous tumor cells (lSO). In humans, it has been shown that 
tumor-stimulated C04+ inducer cells (derived from lymph nodes) may activate 
cos+ suppressor cells (derived from fresh PBL), which in turn prevent the CTL 
response 
Suppressor 
against autologous melanoma tumor cells in vitro (126,127). 
activity by T lymphocytes has also been reported to be present in 
metastatic lymph nodes of patients with cancer of the larynx or bladder (177). 
However, others reported the absence of suppressor activity by T lymphocytes 
among tumor infiltrating lymphocytes (TIL) (1Sl). 
On the basis of the data presented here, we conclude that cos+ 
lymphocytes may be inactivated in vivo and do 
signals provided by the in vitro activated C04+ 
not respond to stimulation 
lymphocytes. The latter 
phenomenon, i.e. poor in vitro lymphocyte functions and mitogenic responses, 
has also been found for TIL (lSl). 
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CHAPTER 4 
ATTEMPTS TO PRODUCE HUMAN CYTOTOXIC LYMPHOCYTE HYBRIDOMAS BY 
ELECTROFUSION AND PEG FUSION 
4.1 Introduction 
The study of lymphocyte-target cell interactions and their interaction 
sites requires large numbers of functionally stable lymphoid cells. An 
important development has been the determination of culture conditions 
allowing the long term maintenance of T lymphocyte clones after cloning in 
limiting dilution (182). In a number of laboratories, including our own, 
culture systems for both specific and nonspecific human cytotoxic T-cell 
clones have been developed (183-185). However, the growth capacity of cloned 
lymphocytes is limited and requires the presence of feeder cells, 
interleukin-2 (IL-2) and other undefined growth factors. To circumvent these 
requirements we attempted to prepare human cytotoxic T-cell hybridomas i.e. 
immortalize the lytic function after somatic cell hybridization. 
Thus far, hybridoma cell lines with cytolytic activity have been 
described occasionally in mouse-mouse and mouse-human systems (144,148-150). 
Failures to establish human cytotoxic T-cell hybridomas have been attributed 
to nonspecific lysis of the tumor cells by the cytotoxic lymphocytes during or 
after the fusion procedure (144). However, the production of human-human 
hybridomas is associated with other difficulties, including establishment of 
initial growth, i.e. proliferation of fused cells was observed only after 
one month (145,146). Moreover, human-human hybridomas frequently showed 
chromosomal instability (147). 
We attempted to overcome these difficulties by using both a modified 
polyethylene glycol (PEG) method and electrofusion (151-153). To avoid the 
putative lysis of the fusion partners during the fusion procedure (144), 
TCRtt~+/CD3+ cytotoxic lymphocytes (CTL) were pretreated by heat shock to 
reversably inactivate the lytic machinery. Tumor cells were not lysed by 
lymphocytes during electrofusion (151,152) and hence pretreatment of the 
lymphocytes was not required. We also used allospecific TCRtt~+/CD3+ CTL clones 
(33,183) without and TCR-/CD3 NK cell clones with lytic activity for the 
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tumor fusion partner. Finally, mouse myeloma B cells were used as (PEG) fusion 
partner for human TCRa~+/CD3+ CTL clones. 
4.2 Materials and methods 
4.2.1 Cells and cell culture 
Human and mouse tumor cell lines used as fusion partners (Table 4.1) were 
cultured in RPM! medium supplemented with 10% (v/v) fetal calf serum (FCS), 2 
mM glutamin and antibiotics. Peripheral blood lymphocytes (PBL) were isolated 
from blood of healthy donors on a Ficoll-Isopaque layer. 
TABLE 4.1 
HUMAN AND MOUSE TUMOR CELL LINES USED AS FUSION PARTNERS 
Human T-lymphoma 
cell lines 
CEM-1 
CEM-2 
JURKAT-1 
JURKAT-2 
HPB-1 
HPB-2 
HSB-1 
Mouse B-myeloma 
cell lines 
SP20 
NS1/X63 
r resistant 
s sensitive 
HATS Ouar 
+ + 
+ 
+ + 
+ 
+ 
+ 
+ 
HATS Ouar 
+ 
+ 
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Mutagenized by 
S.K.H. Foung, Stanford 
University, USA. 
C.M. Croce, Wistar 
Institute, USA. 
S.K.H. Foung, Stanford 
University, USA. 
C.M. Croce, Wistar 
Institute, USA. 
S.K.H. Foung, Stanford 
University, USA. 
C.M. Croce, Wistar 
Institute, USA. 
A. Hagemeyer, Erasmus 
University, The 
Netherlands. 
Mutagenized by 
M. Shulman, Basel 
Institute for Immunology, 
Switzerland. 
J.F. Kearny, University of 
Alabama, USA. 
PBL (10 6 /ml) were cultured in RPM! medium supplemented with 10% human 
serum, 4 mM glutamin and antibiotics, and activated by phytohaemagglutinin 
(PHA) with 10 ~g PHA/ml, for 2 days. Bulk cultured cells and cloned cells are 
listed in Table 4.2. Cloning and expansion was performed in RPM! medium 
supplemented with y-irradiated (40 Gy) PBL and/or B-LCL (lymphoblastoid B-cell 
line) as described elsewhere (33,183,186). 
TABLE 4.2 
HUMAN AND MOUSE TUMOR CELL LINES USED AS TARGET CELLS IN 
Human origin 
K562 
MOLT 
APD 
Licron-My-2 
Mouse origin 
P815* 
CTX ASSAYS 
Source 
erythroid cell 
line 
T-lymphoma 
EBV-transformed 
B-cell line 
B-leukemia 
Obtained by 
G. Cannon, Litton Bionetics 
Kengsinton, U.S.A. 
A. Hagemeijer, Erasmus University 
Rotterdam, the Netherlands 
M. Giphart, Dept. of Immunohematology 
University Hospital, Leiden, 
the Netherlands 
P.A.W. Edwards, Ludwig Institute 
for Cancer Research, Sutten, 
England 
MacDonald, Swiss Institute for 
Experimntal Cancer Research, 
Lausanne, Switserland 
* P815 mouse cells precoated with PHA were used for the lectin-dependent 
cellular cytotoxicity (LDCC) 
Human and mouse tumor cell lines used in cytotoxicity assays (Table 
4.3) were cultured in RPM! medium supplemented with 10% (v/v) FCS, 2mM 
glutamin and antibiotics. 
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TABLE 4.3 
HUMAN CYTOTOXIC LYMPHOCYTES USED AS FUSION PARTNERS 
Cloned cytotoxic 
lymphocytes CD3 
CTL11 + 
CTL20 + 
NK76 
NK77 
CSF1-1 + 
CFS1-7 + 
Uncloned cytotoxic 
lymphocytes 
CSF-1 
CSF-2 
fresh PBL 
PHA-blasts 
MLC-blasts 
4.2.2 Beat treatment 
CD4 CDS CD16 
+ 
+ 
+ 
+ 
+ 
+ 
TCR 
a~ 
a~ 
a~ 
a~ 
Derived from 
PBL healthy donor 
PBL healthy donor 
PBL Ty-lymphocytosis 
PBL Ty-lymphocytosis 
cerebrospinal fluid 
multiple sclerosis 
cerebrospinal fluid 
multiple sclerosis 
PBL healthy donor 
PBL healthy donor 
PBL healthy donor 
To transiently reduce lytic activity, lymphocytes were pretreated by 
heat shock at 46°C for 10 min (144). 
4.2.3 PEG fusion 
was 
The fusion procedure described by 
used with minor modifications as 
Oi et al. (187) for B-fr cell fusions 
described earlier (151). Briefly, 
lymphocytes were mixed with tumor cells at a ratio of 5:1. After PEG fusion, 
the cells were resuspended in RPM! medium supplemented with 20% FCS, 4 mM 
glutamin and cultured (6x104 cells/100 ~1/well) in 96-well microtiter plates 
(Greiner). Gamma-irradiated (40 Gy) murine bone marrow cells (4x10 4 cells/100 
~1/well) were added as feeder cells to initiate proliferation of the fused 
cells. Hybridomas were selected in 0.1 M hypoxanthine, 0.1 M aminopterin, 100 
nM thymidine (HAT), or in 1 ~g/ml azaserine, 0.1 M hypoxanthine (AH) medium. 
In some experiments, ouabain (5x10- 7 M) was added directly after fusion to 
eliminate unfused lymphocytes. One week later, the culture medium was 
supplemented with HAT or AH (or ouabain) at double strength. After 14 days, 
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the medium was replaced by the same medium without azaserin, aminopterin (or 
ouabain). One week later the thymidine and/or hypoxanthine was ommitted from 
the culture medium. In each fusion experiment, tumor-tumor cell fusion 
products, unfused tumor cells and lymphocytes were cultured in HAT or AH 
medium as negative controls. 
4.2.4 Electrofusion 
4.2.4.1 Technique 
The experimental set up used for electrofusion is shown in Figure 4.1. 
It consists of a fusion chamber, a function generator (type 7707, P.Toellner 
Electronics), and a pulse generator (Devices, type 521). 
Figure 4.1 The experimental setup for electrofusion. (A) The fusion chamber, 
under the microscope, connected with (B) a function generator used for pearl 
chain formation. (C) Pulse generator, connected in parallel with the function 
generator, for induction of the electrical breakdown. 
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The fusion chamber (Fig. 4.2) consists of 2 platinum wires (diameter 0.2 
mm) mounted in parallel on a perspex slide at a distance of 0.2 mm. This 
chamber is connected to the function generator, which is used as voltage 
source for an alternating electrical field. 
-
~ ~-
l • 
... - ' /~ 
Figure 4.2 A fusion chamber. Two platinum wires (diameter 0.2 mm) are 
mounted in parallel on a perspex slide at a distance of 0.2 mm. 
A pulse generator was connected in parallel for application of square 
pulses of high field intensities. The electrofusion process can be devided 
into two stages: 
1. "Pearl chain" formation. Cells are brought into close contact with 
each other in a nonuniform alternating electrical field of low intensity 
(field strength 100-250 V/cm; frequency 1-5 MHz). In the alternating 
electrical field, a dipole moment is induced in the cells because of charge 
separation or because of orientation of dipoles in the membrane. Cells then 
migrate in the nonuniform electrical field because the field intensity is not 
equal on both sides of the cells. This phenomenon is known as 
dielectrophoresis. Migration of the dipole-induced cells occurs in the 
direction of the highest field intensity. 
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2. "Fusion". Fusion is induced by the application of a pulse of high 
field intensity (3000-5000 V/cm) and of short duration (10-50 ~sec). An 
electrical breakdown takes place on that part of the membrane (lipid domains) 
where the cells have come into contact with each other. Fusion takes place 
within seconds to minutes, depending on the cell type and species. 
4.2.4.2 Fusion procedure 
The electrofusion procedure of Zimmermann et al. (153) was adapted 
for human T-cell fusions and described earlier (151). To reduce the 
conductivity of the cell suspension without substantially affecting the proper 
osmolarity, tumor cells and lymphocytes were washed three times in a 0.3 M 
mannitol solution before fusion. However, cell aggregates were formed due to 
cell death. After 1 hr, the viability of the cells in the mannitol solution 
was 50%. Therefore, the washing procedure was shortened and carried out at 4°C 
to lower the cell metabolism. Furthermore, other sugars such as glucose 
(enhances survival) and sorbitol were also tested in the washing procedures. A 
0.3 M mannitol: glucose solution [8:1.25 (v/v)] appeared to be optimal. 
Formation of lipid domains (particle free areas) is required for 
pearl chain formation and fusion. It is in these membrane areas that 
cell-cell contact and electrical breakdown takes place. To create lipid 
domains in the membrane, cells were pretreated with pronase (1 mg/ml). The 
proteolytic activity of pronase causes partial degradation of membrane 
proteins, so that mobility of the remaining proteins increases (153). This 
increase in the mobility may facilitate the emergence of the lipid domains in 
the membrane during the exposure to the electrical field. Other enzymes, such 
as dispase and neuraminidase, had no effect. After the washing procedure and 
pretreatment, the cells were transferred to the fusion chamber. 
Pearl chain formation was induced by a field strength of 250 V/cm and 
a frequency of 5 MHz. The intensity of the field pulse applied to induce 
fusion appeared to be critical for subsequent proliferation of the cells. 
Although successful fusions were obtained by pulses of 5000 V/cm during 10 
~sec, no proliferation of fused cells could be induced. Lower pulses of 
prolonged duration were tested. Pulses of 4000 V/cm during 25 ~sec were found 
to be optimal. After fusion, the cells were transferred to the culture medium 
and hybridomas were selected as described for PEG fusion. 
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4.2.5 Determination of cytotoxic activity 
Cytotoxic activity was assayed in a 51 Cr-release test in round-bottom 
microtiter plates as described earlier (164). Briefly, varying cell numbers in 
150 ~l RPM! supplemented with 10% FCS were seeded in the wells before the 
addition of 103 51 Cr-labelled target cells in 100 ~1. Plates were incubated 
for 3 h at 37°C and centrifuged. Supernatant (100 ~l) was collected and 
radioactivity was determined. Specific 51 Cr release was calculated as: 
experimental cpm - spontaneous cpm 
---------------------------------- X 100% 
maximum cpm - spontaneous cpm 
The maximum 51-Cr release was obtained by incubation of the target 
cells with 10% (v/v) Triton X-100. 
4.2.6 Chromosome analysis 
Cells were arrested at the mitotic stage by treatment with 0.025 ~g 
colchicin/ml for 20 min and treated with a hypotonic solution of KCl (0.075 M) 
for 10 min at 37°C. Slides were prepared immediately 
air-dried, and chromosomes were R-banded with acridin-orange 
heat denaturation at 87°C. 
4.2.7 Analysis of membrane antigens 
after fixation, 
(0.01%) after 
The immune phenotype of parental cell lines and hybridomas was 
determined by immunofluorescence analysis using monoclonal antibodies (mAb) 
against CD3 antigens expressed by mature T cells, but not NK cells, CD4 
antigens expressed by helper/inducer T cells, CDS antigens expressed by 
cytotoxic/suppressor T cells, and CD2 antigens expressed by virtually all T 
lymphocytes, HNK-1 antigens expressed by HSB-1 tumor cells, and MHC class I 
and II antigens expressed by the T-cell clones used. Anti-TAC mAb was used for 
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the detection of IL-2 receptors (IL-2R) (CD25), expressed by activated T 
cells. Cells (2x10 5 ) were incubated for 30 min with 40-fold diluted 
fluorescence-isothiocyanate-conjugated (FITC) goat anti-mouse IgG (Nordic, 
Tilburg, The Netherlands). Cells were washed again and analysed on a 
fluorescence-activated cell sorter (FACS II, Becton & Dickinson). 
4.2.8 Invasiveness in hepatocyte cultures 
Invasiveness of the hybridomas was tested in rat hepatocyte cultures as 
described elsewhere (188). Briefly, 6x10 6 cells were added to a 16 mm well 
containing 2x105 rat hepatocytes that had been cultured for 24 hr after their 
isolation. After 4 h the cultures were washed, fixed, dehydrated, detached 
from the dish, and embedded in Epon. Sections of 1 ~m were examined by light 
microscopy. Hybrid cells that were completely surrounded by hepatocytes, or 
located between hepatocytes and substrate were considered as "infiltrated 
cells". As a measure of invasiveness we used the infiltration index 
(infiltrated cells/hepatocyte nuclei). At least 150 hepatocyte nuclei were 
counted in four sections cut at a distance of 20 ~m. 
4.3 Results 
4.3.1 Hybridomas obtained by PEG fusion 
Different human and mouse tumor cell lines were tested for their 
suitability as tumor partner in PEG fusion experiments with cytotoxic 
lymphocytes. Proliferating hybridomas were obtained at between 3-6 weeks after 
fusion with the following tumor cell lines used: HSB-1, CEM-1, CEM-2 and 
JURKAT-2 (Table 4.4). No hybridomas could be generated using JURKAT-1, HPB-1 
and HPB-2 cells as tumor fusion partner. Fusions between cloned CTL20 cells 
(without cytotoxic activity against HSB-1) and HSB-1 tumor cells resulted in 
proliferating hybridomas in 29% of the wells seeded. However, fusions between 
NK76, NK77 or MLC-blasts (with high cytotoxic activity against HSB-1) also 
resulted in proliferating hybridomas (in 17, 37 and 17% of the wells, 
respectively); these cytotoxic lymphocytes were not pretreated by heat shock 
to reduce cytotoxic activity (Table 4.4). Hybridomas of "effector" cells and 
CEM-1 or JURKAT-1 tumor cells are ouabain resistant. "Normal" effector 
lymphocytes were expected to rapidly die in the presence of ouabain. However, 
it was found that this only occurred after 2-3 days, during which period 
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cytotoxic activity was not depressed (data not shown). No differences were 
found in the yield of hybridomas with or without ouabain (Table 4.4); in both 
cases 3% of the wells seeded contained hybridomas, using CEM-1 cells as tumor 
fusion partner, and none with JURKAT-1 tumor cells. Fusions with JUill<AT-2 
tumor cells yielded hybridomas in 30% of the wells seeded with all CTL used. 
TABLE 4.4 
YIELD OF HUMAN-HUMAN HYBRIDOMAS AFTER PEG FUSION 
Lymphocyte fusion Tumor fusion Percent yield of 
partner partner hybridomas 
fresh PBL HSB-1 0 (900) 
fresh PBL* HSB-1 11 (900) 
PHA-blasts HSB-1 0 (900) 
MLC-blasts HSB-1 17 (350) 
clone CTL20 HSB-1 29 (400) 
clone NK76 HSB-1 17 (100) 
clone NK77 HSB-1 37 (100) 
fresh PBL CEM-1** 3 (100) 
clone CTL20 CEM-1** 3 (100) 
MLC-blasts CEM-2 10 (180) 
uncloned CSF-1 CEM-2 10 (172) 
urrcloned CSF-2 CEM-2 10 (196) 
clone 1, CSF-1 CEM-2 10 (180) 
clone 7, CSF-1 CEM-2 10 (172) 
fresh PBL JURKAT-1** 0 (100) 
clone CTL20 JURKAT-1** 0 (100) 
uncloned CSF-1 JURKAT-2 30 (190) 
uncloned CSF-2 JURKAT-2 30 (180) 
clone 1, CSF-1 JURKAT-2 30 ( 96) 
clone 7, CSF-1 JURKAT-2 30 ( 96) 
MLC-blasts JURKAT-2 30 (190) 
Numbers between parentheses indicate total number of wells seeded. 
* effector cells were pretreated by heat shock 
** tumor cells were HAT-sensitive as well as ouabain-resistant 
Finally, SP20 and NS1/X63 mouse myeloma cell lines were also tested for 
their suitability as fusion partners in PEG fusion experiments with human CTL 
clones. None of the human CTL clones lysed mouse tumor cell partners, and thus 
heat shock was not necessary. PEG fusion between SP20 mouse myeloma cells and 
the human cytotoxic T-cell clones CTL11 and CTL20 resulted in rapidly 
proliferating hybridomas in 19-28% of the wells at between 1-2 weeks after 
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fusion (Table 4.5). Using NS1/X63 mouse myeloma cells as fusion partners, 
proliferation was observed in 1-2% of the wells (Table 4.5) at between 2-3 
weeks. These latter hybridomas proliferated very slowly and died at between 
1-2 months. 
TABLE 4.5 
YIELD OF HUMAN-MOUSE HYBRIDOMAS AFTER PEG FUSION 
Human T-lymphocyte Mouse tumor fusion percent yield 
fusion 2artner partner hybridomas 
clone CTLll SP20 19 (250) 
clone CTLll SP20 28 (250) 
clone CTL20 SP20 20 (250) 
clone CTLll NS1/X63 2 (250) 
clone CTL20 NS1/X63 2 (250) 
Numbers between parentheses indicate the total numbers of wells 
seeded. 
4.3.2 Comparison between PEG fusion and electrofusion 
of 
A comparison was made between PEG 
to the frequency of hybridomas obtained 
used (Table 4.6). 
fusion and electrofusion with respect 
for the different tumor cell lines 
TABLE 4.6 
YIELD OF HUMAN-HUMAN HYBRIDOMAS BY PEG FUSION 
AND BY ELECTROFUSION 
fusion partners percent yield of hybridomas 
T lymEhocytes tumor cells PEG fusion electrofusion 
fresh PBL HSB-1 0 (900) 99 (200) 
PHA-blasts HSB-1 0 (900) 1 (200) 
clone CTL20 HSB-1 29 (400) 69 (400) 
clone CTL20 CEM-1 3 (100) 3 (100) 
clone CTL20 HPB-1 0 (100) 0 (100) 
clone CTL20 JURKAT-1 0 (100) 0 (100) 
Numbers between parentheses indicate the total numbers of wells 
seeded. 
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Rapidly proliferating hybridomas were obtained at between 3-6 weeks 
after fusion. Using HSB-1 as tumor fusion partner, electrofusion appeared to 
be more efficient than PEG fusion, as illustrated by a higher yield of 
hybridomas obtained under the same culture conditions. The electrofusion 
process, i.e. collection and fusion of cells, is shown in Figure 4.3.1 and 
4.3.2. Microscopy revealed no lysis of the tumor cells, and thus heat shock of 
the lymphocytes was not necessary. The best results with electrofusion were 
obtained with uncultured PBL; 99% of the wells seeded yielded hybridomas. This 
corresponded with the high fusion frequency observed in microscopy. Using PEG, 
no hybridomas were obtained between HSB-1 tumor cells and uncultured PBL, 
which may be due to non-specific lysis of HSB-1 tumor cells by the PBL. The 
yield of hybridomas between HSB-1 and cloned CTL20 cells (without cytolytic 
activity against HSB-1) was also higher after electrofusion than after PEG 
fusion (69 and 29%, respectively). No hybridomas were obtained from PEG 
fusions between HSB-1 tumor cells and PHA-activated lymphocytes. During 
electrofusion, a low fusion frequency was observed between these fusion 
partners and only a few hybridomas were obtained (1% of the wells seeded). In 
PEG fusion and electrofusion a low yield (3% of the wells seeded) of 
hybridomas was observed using CEM-1 as tumor fusion partner, and no yield with 
JURKAT-1 and HPB-1 tumor cells (Table 4.6). Nevertheless, a high frequency of 
fusions was observed under the microscope with CEM-1 tumor cells during 
electrofusion. JURKAT-1 tumor cells collapsed during the electrofusion process 
and HPB-1 tumor cells did not fuse. 
4.3.3 Cytotoxic activity of hybridomas 
More than 500 of the human-human hybridomas obtained were tested for 
CTX in 51 Cr release assay. Only three (obtained by electrofusion of clone 
CTL20 and HSB-1 tumor cells) showed CTX (albeit at low levels) against APD, 
the original stimulator cells of clone CTL20. Hybridomas of MLC-responder 
blast cells with CEM-2 or JURKAT-2 tumor cells showed low levels of CTX 
against K562 and also against the stimulator cells after overnight incubation 
of the hybridomas with non-T stimulator cells. 
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Figure 4.3.1 Pearl chain formation of a large tumor cell and a small 
lymphocyte in an alternating electrical field. 
Figure 4.3.2 Fusion is induced between a large tumor cell and a small 
lymphocyte after application of an electrical breakdown pulse. 
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Of more than 100 human-mouse hybridomas tested for CTX only 1 (between 
CTL11 and SP20) showed high CTX (49%) against Licron Hmy-2 at an 
effector/target ratio of 27/1. One week later the CTX of the hybrid cells had 
decreased to 12% lysis of target cells, and after 2 weeks no activity was 
left. 
4.3.4 Karyotypes of.hybridomas 
In human-human hybridomas chromosomes derived from the tumor cells 
could not be distinguished. All hybridomas obtained with HSB-1 as tumor cell 
fusion partner showed the translocations derived from the tumor cell line. 
However, no specific marker chromosomes, derived from the lymphocytes, were 
observed, such as chromosome 16 with a centromeric polymorphism (clone CTL20). 
Most of the hybridomas between HSB-1 tumor cells and PBL, cloned CTL11 or 
cloned CTL20 cells contained the same number of chromosomes as HSB-1 tumor 
Figure 4.4 R-banded chromosomes from a xenogeneic hybrid cell. The hybrid 
cell contains human (see arrows) and mouse chromosomes. 
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Some hybridomas contained more chromosomes than either of the parental 
cell lines. In addition, some hybridomas of HSB-1 tumor cells and clone CTL20 
cells revealed newly formed .polymorphisms which were absent from HSB-1 tumor 
cells and lymphocytes (results not shown). Most of the hybridomas of CEM-1 
tumor cells and cloned CTL20 cells were not identified. Hybridomas with CEM-2 
and JURKAT-2 were not analyzed. 
Hybridomas between SP20 mouse myeloma cells and cloned CTL11 or cloned 
CTL20 cells were identified by the presence of easily distinguishable human 
and mouse chromosomes (Figure 4.4). These hybridomas contained 2-13 human 
chromosomes (Table 4.7). Chromosome 16 from clone CTL20 was also clearly 
identified. There was no indication of a selective loss of human chromosomes. 
Hybridomas between NS1/X63 mouse myeloma cells and cloned CTL11 or CTL20 cells 
had died before karyotyping was possible. 
TABLE 4.7 
CHROMOSOME ANALYSIS OF XENOGENEIC HYBRIDOMAS 
(HUMAN) CLONE CTL20 - (MOUSE) SP20 
Cell number Human chromosomes 
1 1 6 12 15 16 17 20 X 
2 7 15 17 20 X 
3 6 19 20 
4 6 8 9 13 15 15 
5 1 6 17 17 19 
6 1 6 6 19 
7 1 6 7 10 10 14 15 16 17 X 
8 1 6 10 10 17 20 
9 1 3 3 6 6 8 9 10 10 12 16 17 19 
10 1 3 4 5 6 9 12 20 
11 1 3 4 4 6 6 9 10 10 12 17 19 19 
12 6 17 
13 3 6 7 11 20 
4.3.5 Expression of membrane antigens 
Membrane antigen expression was determined on both parental cells and 
their fusion products. All hybridomas, obtained after PEG fusion and 
electrofusion using HSB-1 as parental tumor cells, expressed HNK-1 antigens 
derived from HSB tumor cells but none of the lymphocyte markers could be 
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detected. Likewise, all hybridomas obtained with CEM-1, CEM-2 and JURKAT-2 
cells as tumor fusion parents expressed the membrane antigens derived from the 
tumor cell line. CEM-1 is CD3-, but CEM-2 and JURKAT-2 tumor cells are CD3+. 
Two of the hybridomas of cloned CTL20 cells and CEM-1 tumor 
low levels of CD3 antigens derived from the lymphocytes. 
cells expressed 
None of the 
hybridomas expressed IL-2R after PHA or allogeneic stimulation, or after 
incubation with high concentrations of IL-2. 
Some xenogeneic hybridomas between SP20 mouse myeloma cells and cloned 
CTL20 cells expressed low levels of MHC class II antigens derived from clone 
CTL20. 
4.3.6 Invasiveness of hybridomas 
Some of the hybridomas between the non-invasive tumor cell line HSB-1 
tumor cells and invasive cloned CTL20 cells were found to be highly invasive 
in cultured rat hepatocytes (Table 4.8). 
TABLE 4.8 
INVASIVENESS OF HUMAN-HUMAN AND HUMAN-MOUSE HYBRIDOMAS 
Human-human hybridomas Fusion nr Infiltration index 
CTL20xHSB-1 72 (1) 0.41* 
CTL20xHSB-1 72 (2) o. 77* 
NK77xHSB-1 76 (1) 0.09 
human-mouse hybridomas 
CTL20xSP20 125 (4) 0.00 
CTLllxSP20 115 (A1) 0.01 
tumor cell lines 
HSB-1 0.05 
SP20 0.01 
T lymphocytes 
PBL unstimulated 0.06 
PBL stimulated (PHA) 0.74 
* Cells with invasive properties. 
Infiltration index = number of cells infiltrated per 100 rat 
hepatocytes. 
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The level of invasiveness (I.I infiltration index) of fusions 
between HSB-1 and CTL20 is 16 times higher (I.I = 0.77) than that of HSB-1 per 
se (I.I = 0.05), and equals that of stimulated T lymphocytes (I.I = 0.74) . 
. Hybridomas of CEM-1 tumor cells and cloned CTL20 cells showed low invasiveness 
(data not shown). Fusions using CEM-2 and JURKAT-2 as tumor fusion partner 
were not tested. The human-mouse hybridomas tested were not invasive (Table 
4.8). 
4.4 Discussion 
of 
In the present 
human TCR~~+/CD3+ 
study proliferating hybridomas were obtained by fusion 
CTL or TCR-/CD3- NK cells and human T-lymphoma cells 
either by PEG or electrofusion. In experiments using HSB-1 cells as a tumor 
partner, more proliferating hybridomas were obtained under the same culture 
conditions with electrofusion than with the PEG fusion. This could be due to 
either higher fusion frequencies or better survival of the hybridomas after 
electrofusion. In contrast to PEG fusion, the electrofusion process can be 
visualized by microscopy and thus offers information on fusion frequencies in 
relation to yield of hybridomas. Remarkably high fusion frequencies using 
CEM-1 as tumor fusion partner did not result in a high yield of proliferating 
hybridomas. Thus, it appears that in addition to a high fusion frequency other 
factors are important for the generation of proliferating human T/NK-cell 
hybridomas and these are cell type dependent. 
The results obtained by electrofusion unequivocally demonstrated that 
fusion efficiency depends both on the tumor cell and T/NK lymphocyte subset. 
High fusion efficiencies were obtained with HSB-1 and CEM-1 tumor cells, 
whereas virtually no fusions were observed with JURKAT-1 and HPB-1 tumor 
cells. This is consistent with the data of Roos et al. (189) who demonstrated 
by freeze-fracture electron microscopy that not every tumor cell line can be 
fused by PEG. It appears that aggregation of intermembrane particles, a 
prerequisite for PEG-induced cell fusion, does not occur in fusion-deficient 
cells, at non-toxic PEG concentrations. It is not clear from our results 
whether pretreatment with heat shock of the CTL to transiently reduce the CTX, 
is indeed a prerequisite for the production of cytotoxic T-cell hybridomas as· 
previously suggested by Kaufmann et al. (144). These authors speculated that 
the lymphocytes would lyse tumor cells and/or hybridomas during or after the 
fusion procedure. Some of the results are in contrast with,this suggestion. 
For instance, no differences were found in the yield of hybridomas between 
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fusions of untreated PHA-blast cells (with high cytotoxic activity) with HSB-1 
tumor cells, and fusions of heat-treated PHA-blast cells (cytotoxic activity 
was transiently reduced to zero) with HSB-1 tumor cells. However, no 
hybridomas were obtained by either procedure. Furthermore, untreated 
MLC-blasts cells, clone NK76 and NK77 (with high cytotoxic activity against 
HSB-1 tumor cells) yielded hybridomas in 17, 17 and 37% of the wells, 
respectively, when fused with HSB-1 tumor cells, while no hybridomas were 
expected if the lytic effector cells would lyse the tumor cell fusion partner. 
Using CEM-2 or JURKAT-2 as tumor fusion partner, hybridomas were obtained in 
10 and 30% of the wells, respectively, for each type of CTL used. 
On the other hand, the results obtained with fusions between PBL and 
HSB-1 tumor cells supported the suggestion of Kaufmann et al. (144). Here, 
heat-treatment of PBL resulted in an increased yield of hybridomas; 
heat-treated PBL and HSB-1 tumor cells yielded hybridomas in 11% of the wells, 
while 
These 
of CTX 
no hybridomas were obtained 
varying results suggest that 
of the T lymphocytes against 
with untreated PBL and HSB-1 tumor cells. 
there is no relation between the presence 
the tumor fusion partner and the yield of 
hybridomas (cytotoxic or non-cytotoxic). 
Of more than 600 hybridomas tested for CTX only 3 human-human 
hybridomas and 1 human-mouse hybridoma showed transient CTX against specific 
and nonspecific target cells, respectively. Some of the human-human hybridomas 
tested were highly invasive in rat hepatocyte cultures and others expressed 
lymphocyte derived (CD3) antigens. However, we never found these lymphocyte 
derived properties together in a single hybridoma. According to Foung et al. 
(147), most of the cytotoxic T/NK-cell hybridomas we obtained showed 
chromosomal instability. 
The hybridomas we obtained usually had the immunophenotype of the 
tumor cell parent and not of the lymphocyte cell parent. This can be explained 
by preferential loss of the lymphocyte-derived chromosomes. Because the 
genetic information in lymphocytes for the process of target cell binding, 
recognition and lysis is located on different chromosomes, lysis can only 
occur if the hybridomas contain all these chromosomes. We have analyzed a 
number of xenogeneic hybridomas in which the human and mouse lymphocyte 
chromosomes could easily be distinguished. The results obtained are 
illustrative for the problems encountered in attempts to immortalize a complex 
immune function like CTX (binding, recognition ·and lysis). Firstly, in Table 
4.7 it is shown that xenogeneic hybridomas varied greatly regarding their 
number of human chromosomes. Secondly, a number of xenogeneic hybridomas 
contained 2 copies of chromosome 6 (with genes coding for MHC antigens), while 
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no MHC Class I antigens were detected using mAb against these antigens. This 
lack of MHC expression could be the result of genetic repression of genes 
coding for MHC Class I antigens by tumor-derived gene products. Alternatively, 
the expression of MHC-genes on chromosome 6 may be co-regulated by products of 
genes located on other human chromosomes. In this context, van Dongen et al. 
(190) demonstrated that expression of the TCR~~/CD3 receptor complex, 
dete~table by mAb, only occurs when chromosome 11 (CD3-o, CD3-E and CD3-y 
genes), chromosome 7 (TCR~ genes) as well as chromosome 14 (TCR~-genes) 
were present in the hybridomas. Finally, the MHC type of the parental cells 
may be altered after fusion as a result of redistribution of MHC antigens in 
the membrane (191). If so, the use of mAb for the detection of MHC antigens is 
not adequate, i.e. MHC mRNA levels in the hybridomas might be normal whereas 
MHC antigens on the membrane are altered or lack those epitopes recognized by 
the mAb used. Hence, alteration of the membrane molecule distribution on the 
hybridomas may lead to reduction or loss of nonspecific binding and/or 
recognition capacity of target cells, and thus of CTX. These various factors 
may account for the low success rate in the production of cytotoxic T/NK-cell 
hybridomas. In contrast most of the T-cell hybridomas produced in human, mouse 
or xenogeneic systems display immortalized immune functions, such as release 
of lymphokines (interleukin-2, macrophage-activating factor, and B-lymphocte 
replication factor) (140,143,145-147). The production of lymphokine(s) may 
involve fewer genes, located on less different chromosomes than cytolytic 
funtions. For instance, IL-2 mRNA is produced by one gene located on 
chromosome 4 (192). 
Our results demonstrate 
electrofusion, are efficient tools 
that PEG fusion, and in particular 
to produce human T/NK-cell hybridomas. 
However, somatic cell hybridization does not allow the immortalization of CTX. 
Other strategies, such as DNA-mediated transfer of genes endowing human 
cytotoxic cells with unlimited proliferative capacity, may be more successful, 
since (a) chromosomal instability is not involved here, and (b) trans[~r of 
proliferative capacity seems less complicated than transfer of CTX. 
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CHAPTER 5 
ONCOGENE EXPRESSION AND INTERLEUKIN-2 RECEPTOR LEVELS IN NORMAL AND 
MALIGNANT TCRtt~+/CD3+ AND TCR-/CD3- HUMAN LYMPHOCYTES 
5.1 Introduction 
Several lines of evidence suggest a role for the c-myc oncogene in cell 
proliferation (193-195). Expression of c-myc is constitutively enhanced in 
Burkitt lymphomas after translocation of the c-myc gene (196,197). Enhanced 
c-myc expression is associated with amplification of the c-myc gene locus in 
human colon carcinoma APUDoma Colo 320 (198) and in the human promyelytic 
leukemia HL60 cells (199). The expression of c-myc in HL60 is more related to 
cell differentiation than to proliferation (199). The c-myc gene is inducible 
in normal cells and regulated by growth signals which promote proliferation, 
e.g. in mouse fibroblasts by platelet-derived growth factor, in mouse B 
lymphocytes by lipopolysaccharides and in mouse T lymphocytes by lectin 
activation (87). 
One of the functions of c-myc protein products is to promote an 
acquisition of competence to respond to exogenously added growth factors 
(87,200,201). However, induction of myc expression in normal human lymphocytes 
may not be sufficient for acquisition of competence to proliferate (202). Gene 
transfer experiments with fibroblasts suggests that the multistep process of 
transition from primary cells to fully transformed ones requires functional 
complementation between two or more transforming genes (194,202-204). In 
contrast to this theory, Spandidos and Wilkie (205) claimed that mutated 
Ha-ras-1 gene, if linked to a strong transcriptional promotor, may not require 
a cooperating gene to induce malignant transformation of early passage rodent 
cells. 
Proliferation of T and B lymphocytes requires the interaction of 
interleukin-2 (IL-2) with its receptors (206-209). IL-2 is the growth hormone 
for activated T lymphocytes (210). The expression of IL-2 receptors (IL-2R) on 
resting T cells can be induced by phytohaemagglutinin (PHA) (210,211). 
PHA-induced T-cell activation occurs via the TCRtt~/CD3 complex (212,213). We 
have shown that cross-linked anti-CD3 monoclonal antibody (mAb) and PHA are 
able to induce cytolytic activity in TCRtt~+/CD3+ but not in TCR-/CD3- clones 
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(17), and concluded that the CD3 receptor serves as a site for signal 
transduction. 
In the present study we have investigated the involvement of the CD3 
receptor in c-myc and IL-2R expression. To this aim we used cloned normal 
human TCR-/CD3- NK and TCR~~+/CD3+ T cells as well as malignant TCR-/CD3- and 
TCR~~+/CD3+ T-lymphoma cells. To study a possible cooperation between the 
expression of ras and myc we compared mRNA levels of both genes in highly and 
poorly proliferating TCR~~+/CD3+ T cell and TCR-/CD3 NK-cell clones, 
respectively. 
5.2 Materials and Methods 
5.2.1 Human blood lymphocytes 
Peripheral blood lymphocytes (PBL) were Ficoll-isolated from blood of a 
healthy donor. PBL (1x10 6 cells/ml) were cultured in RPM! medium supplemented 
with 10% v/v human serum, 4 mM glutamin and penicillin/streptomycin, and 
activated by PHA (10 ~g PHA/ml) for 1,2 or 3 days, respectively. 
5.2.2 Cloned TCR~+/CD3+ cells and TCR-/CD3- NK cells 
The following (cytotoxic or noncytotoxic) T cell and NK cell clones 
were used: T0+8 (TCR~~+/CD2+,CD3+,CD4+) and CTL9, CTL11, P+2, T0+7 
(TCR~~+/CD2+,CD3+,CD8+), NK76, NK77, NK468 (all CD2+,CD3-,CD4-,CD8-). Clones 
were obtained by limiting dilution (163) and cultured in RPM! medium 
supplemented with 10% (v/v) human serum, 4mM glutamine, 1 ~g/ml 
leucoagglutinin (purified PHA), 5% (v/v) IL-2 and penicillin/streptomycin. 
Gamma-irradiated (20Gy) Epstein-Barr virus-transformed human lymphoblastoid B 
cell lines (1 x 104 cells/200 ~1) and PBL (10 x 104 cells/200 ~1) were added 
as feeder cells. Cells were cultured in round-bottom 96-well microtiter plates 
at 37°C, 5% co2 and replated weekly with y-irradiated (20Gy) fresh feeder 
cells and medium. 
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5.2.3 Tumor cell lines 
Human T lymphoma cell lines, CEM (TCR-/CD2-,3-), JURKAT 
(TCR~~+/CD2+,3+)(kindly provided by Dr. S.K.H. Foung, Stanford University 
Medical Center, USA) and MOLT-4 (TCR-/CD2-,3-) (kindly provided by Dr. A. 
Hagemeyer, Erasmus University, Rotterdam, The Netherlands) were used. The 
JURKAT cell line (J3R7) used in these experiments did not produce IL-2 (l47). 
Cells were cultured with and without PHA in RPM! medium containing 10% v/v 
fetal calf serum (FCS), heat-inactivated, 2 mM glutamin and penicillin/ 
streptomycin. 
5.2.4 Assay for oncogene expression 
Levels of c-myc and e-ras mRNA were determined by means of a dot blot 
assay (154) using the commercially available quick blot kit (Schleicher and 
Schuell). The human c-myc (DNA) probe isolated from the colon carcinoma 
APUDoma Colo 320 (198) was kindly provided by Dr. H.E. Varmus (Department of 
Microbiology and Immunology, University of California, CA). A fixed number of 
cells was spotted on a nitrocellulose filter (number of cells are specified in 
Tables 5.1-5.4. The hybridization procedure is described elsewhere (214). 
Briefly, the plasmid was labelled with 32 P-dCTP (Radiochemical Center, 
Amersham, UK) to high specific activity 1-Sx108 cpm/~g), using a 
nick-translation kit (Amersham), according to the manufacturers instructions. 
The filters were preincubated in a hybridization solution containing 50% 
formamide, 3xSSC (lxSSC is O.lSM NaCl, O.OlSM Na-citrate), 1% sodium dodecyl 
sulfate (SDS) and lOx Dennhardt's solution (lx Dennhardt's solution is 0.2% 
Ficoll, 0.2% bovine serum albumin, 0.2% polyvinylpyrrolidone). Radioactively 
labelled probe fragments were then heat-denaturated, incubated with the 
filters for at least 16 hat 42°C in a final concentration of l-Sx106 cpm/ml). 
After incubation, the filters were rinsed in 2xSSC and subsequently washed at 
65°C in 3xSSC, 0.1% SDS, in lxSSC, 0.1% SDS and twice in 3xSSC, 0.1% SDS, for 
30 min. After a short wash in 2xSSC at room temperature, the filters were 
autoradiographed (Kodak X-OMATIC, AR2 film) at -70°C using X-OMATIC 
intensifying screens. 
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5.2.5 Determination of IL-2R 
Cells (2x10 5 ) were incubated with the anti-Tac mAb (kindly provided by 
Dr. T. Uchiyama, Kyoto Universty Hospital, Kyoto, Japan) which identifies the 
IL-2R. The cells were then washed with phosphate buffered saline, supplemented 
with 1% bovine serum albumin, 0.1% sodium azide and incubated with anti-TAC 
mAb plus a second layer of fluorescein isothiocyanate (FITC) labelled 
goat-anti-mouse-antiserum (Nordic, Tilburg, The Netherlands). As a control for 
background fluorescence, cells were incubated with goat-anti-mouse-antiserum 
alone. Stained cells were analyzed using a fluorescence-activating cell sorter 
(FACS II, Becton & Dickinson). Percentages of IL-2R+ and IL-2R- cells were 
calculated from the fluorescence histograms. Total levels of IL-2R were 
determined by cumulation of the fluorescence intensities (as measured with a 
logarithmic amplifier) of a fixed number of cells (IL-2R- and IL-2R+ cells). 
This was done to allow direct comparison with the levels of c-myc mRNA, which 
were also measured as an average of a fixed number of cells. To obtain linear 
values, the cumulative fluorescence intensities were calculated by multiplying 
the number of events in each channel (CHN) of the fluorescence histograms with 
2cHN/ 17 : a difference of 17 CHNs represents a 2-fold difference of 
fluorescence intensity. The fluorescence intensities are given in arbitrary 
units. 
5.3 Results 
5.3.1 Expression of c-myc and IL-2R in resting and PBA-activated lymphocytes 
In resting PBL, expression of IL-2R and c-myc was below the detection 
level under the experimental conditions applied. After PHA activation, a 
strong increase in the expression of both c-myc and IL-2R was found over the 
first 2 days, but at day 3 lower levels of c-myc mRNA and IL-2R were observed 
as well as a drop in the percentages of IL-2R+ cells (Table 5.1). In all 
subsequent experiments resting and PHA-activated PBL were routinely used as 
negative and positive control cells, respectively. 
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TABLE 5.1 
LEVELS OF c-MYC mRNA AND IL-2R+ IN PHA ACTIVATED LYMPHOCYTES 
Days *** total level* percent of IL-2R+ c-myc expression** 
PHA 
0 22 0 
1 32 37 1 •• ·-~;,)•· 
' >,1 'j), ~$ 
2 187 72 
-· 
•) 
3 158 62 : ••. 
* total levels of IL-2R in arbitrary units of fluorescence 
** each dot blot dilution series represent c-myc mRNA from 160,000, 
53,000, 18,000 and 6,000 cells. 
***days of incubation with PHA 
5.3.2 Expression of c-myc and IL-2R in TCRaa+/CD3+ T- and TCR-/CD3- NK-
cell derived clones. 
Table 5.2 shows the expression of c-myc and IL-2R in human TCR~S+/CD3+ 
T-cell clones (cytotoxic and noncytotoxic) and TCR-/CD3- NK cell derived 
clones which were cultured in the complete expansion medium, i.e. containing 
PHA, feeder cells and IL-2. All T-cell clones expressed both c-myc and IL-2R. 
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TABLE 5.2 
DIFFERENT LEVELS OF c-MYC mRNA AND IL-2R IN 
TCR~~+/CD2+,3+ AND TCR-/CD2+,3- CLONES 
clone phenotype PHA total level* positive cells c-myc 
(percent) expression** 
CTL9 CD2+,3+ + 449 79 •• • • 
CTLll CD2+,3+ 183 29 • 
,, ' . . 
CTL11 CD2+,3+ + 
-· 
-AI .... 535 84 
P+2 CD2+,3+ + 602 89 •••• • 
T0+7*** CD2+,3+ + 597 89 ••• • T0+8*** CD2+,3+ + 746 91 •• • • NK468*** cD2+,3- + n. t. n. t. ,· 
---------·-
NK76*** CD2+,3- 260 42 
• 
NK76*** CD2+,3- + 395 53 
• 
NK77*** CD2+,3- 182 43 
NK77*** CD2+,3- + 376 58 
• 
* total levels of IL-2R in arbitrary units of fluorescence 
** each dot blot dilution series represents c-myc mRNA from 160,000, 
80,000, 40,000 and 20,000 cells; for clone CTL11 the dilution series 
represents c-myc mRNA from 160,000, 53,000, 18,000 and 6,000 cells. 
*** derived from a patient with Ty lymphocytosis 
Contamination of feeder cells in the evaluation of IL-2R and c-myc 
expression can be excluded because the feeder cells desintegrated in about 7 
days as described in detail earlier (33). The TCR~~+/CD3+ clones (CTL9, CTL11, 
P+2, T0+7, and T0+8) showed manifold higher levels of c-myc mRNA and a 2-fold 
higher level of IL-2R than the TCR-/CD3- clones (NK76, NK77, and NK468). A 
representative example of the determination of IL-2R on a TCRa~+/CD3+ and a 
TCR-/CD3- clone is shown in Figure 5.1. The significance of the observed 
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levels of c-myc mRNA in TCR-/CD3- clones was demonstrated by the absence of 
any c-myc specific hybridization signal with these cells after deprivation of 
IL-2, PHA and feeder cells (data not shown) . 
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Figure 5.1 Fluorescence histograms of IL-2 receptors expressed on a 
TCRtt~+/03+ T-cell clone and a TCR-/CD3 NK-cell clone. Both clones were 
cultured in the presence of PHA in the expansion system. 
In the absence of PHA, but in the presence of feeder cells and IL-2, 
decreased levels of IL-2R were observed on both the TCRtt~+/CD3+ clone CTLll 
and TCR-/CD3- clones NK76 and NK77 (Table 5.2). In the same culture a 
decreased level of c-myc mRNA in the TCRtt~+/CD3+ clone CTLll was found (Table 
5.2). For the TCR-/CD3- NK-cell clones such a decrease was not observed or 
fell below the detection level of the method. 
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5.3.3 Expression of c-myc and IL-2R in TCR«~+/CD3+ and TCR-/CD3- T-lymphoma 
cell lines 
Table 5.3 shows the expression of c-myc and IL-2R in human T lymphoma 
cell lines cultured with and without PHA. All three cell lines, CEM, MOLT and 
JURKAT constitutively expressed c-myc. Only JURKAT (CD3+) responded to PHA 
with a manifold increase in the c-myc mRNA level (Table 5.3). No increase was 
observed in the CD3- T-lymphoma cell lines. In contrast to normal lymphocytes, 
none of the malignant T-lymphoma cell lines expressed IL-2R. 
TABLE 5.3 
LEVELS OF c-MYC mRNA AND IL-2R IN MALIGNANT HUMAN TCR«~+/CD2+,3+ AND 
TCR-/CDZ-,3 T-LYMPHOMA CELL LINES 
IL-2R 
T lymphoma phenotype PHA total level* IL-2R pos cells c-myc 
cell line percent expression** 
MOLT CD2-,3 43 0 • • 
,. 
• 
MOLT CD2-,3 + 56 0 
• • • • 
CEM CD2-,3 49 0 
---· CEM CD2-,3- + 54 0 ••• 
., 
JURKAT coz+,3+ 38 0 
• • JURKAT CD2+,3+ + 50 0 
•••• 1 
* total levels of IL-2R in arbitrary units of fluorescence 
** each dot blot dilution series represents c-myc mRNA from 160,000, 
80,000, 40,000 and 20,000 cells 
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5.3.4 Expression of c-myc and e-ras in TCR«~+/CD3+ T- and TCR-/CD3-
NK-cell clones 
In these experiments we increased the detection level (assay 
sensitivity) of mRNA amounts since the expression of e-ras appeared to be much 
lower than that of c-myc. We therefore performed proteinase K digestion at 
60°C instead of 37°C. Resting and PHA-activated lymphocytes were used as 
control cells. Table 5.4 shows the expression of c-myc and e-ras mRNA levels 
in cloned TCR«~+/CD3+ T- and TCR-/CD3- NK-cells. When c-myc mRNA levels were 
high, e-ras mRNA levels were also high and, vice versa, when the c-myc mRNA 
level was low, the e-ras mRNA level was low. Like c-myc expression, the e-ras 
mRNA level is higher in TCR«~+/CD3+ T cells than in TCR-/CD3- NK cells. The 
level of c-myc and e-ras mRNA correlates directly with the proliferative 
capacity of the cells, i.e. high levels of c-myc and e-ras mRNA corresponded 
with high cell yields. 
5.4 Discussion 
We studied the relative involvement of the TCR«~+/CD3 complex in the 
regulation of c-myc and IL-2R expression. 
TCR«~+/CD3+ and TCR-/CD3- NK cells as 
TCR-/CD3- T-lymphoma cell lines were used. 
To this aim cloned normal human 
well as malignant TCR«~+/CD3+ and 
PBL were used as control cells, 
i.e. PHA activation of resting PBL induces a sharp but transient increase in 
IL-2R and c-myc expression. All cloned TCR-/CD3- NK and TCR«~+/CD3+ T cells 
expressed c-myc and IL-2R when cultured in complete expansion medium. The 
TCR«~+/CD3+ T-cell clones (CTL9 CTL11, P+2, T0+8) showed about 2-fold higher 
levels of c-myc mRNA than the TCR-/CD3- NK cell-derived clones (NK76 and NK77 
and NK468). These differences in c-myc mRNA and IL-2R levels for TCR«a+/CD3+ 
T-cell and TCR-/CD3- NK-cell clones plus the fact that PHA transduces its 
signal via the CD3 receptor (29,212,213), suggest that in TCR«a+/CD3+ T-cell 
clones the lectin-induced c-myc expression occurs via the CD3 receptor. 
However, TCR-/CD3- NK-cell clones do express IL-2R and c-myc, albeit at lower 
levels (Table 5.2) and hence, (an) activation site(s) other than CD3, 
mediating the induction of IL-2R and c-myc, must exist. Such a distinct 
activation site on T cells could be the CD2 50KD sheep red blood cell 
receptor. The CD2 receptor is present on both mature TCR«a+/CD3+ T-cell clones 
and cloned TCR-/CD3- NK cells. Under appropriate conditions CD2 serves as a 
regulatory site for proliferation (29). Moreover, a single anti-CD2 mAb 
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0 
Clones Phenotype 
CTLZO CD3+,4+,8-
CTLll CD3+,4-:-,8+ 
P+2 CD3+,4-,8+ 
NK76* ~03-,4-,8 -
NK77* :o3-,4-,8-:-
NK472* CD3-,4-,8 -
PBL(-PHA) 
PBL(+PHA) 
TABLE 5.4 
c-MYC and e-RAS mRNA LEVELS IN HUMAN TCRa~+/CD3+ AND TCR-/CD3- CLONED 
LYMPHOCYTES 
percent yield c-myc mRNA level** e-ras mRNA level** 
of cells 
--
4861 
-
... .. 
5468 .._ 
--
• 
9513 ,_. .. .. i .. 
-
' 
-' 
.. 
1747 
1500 ....... • .... 
1700 
....... ..... 
.. . ""' 
f 
--· 
- -
.. .. -~·, 
* derived from a patient with Ty lympho~ytosis 
** each slot blot dilution series represent mRNA for 160,000, 80,000 and 40,000 cells 
reportedly inhibits PHA-induced c-myc expression (201). We have shown that 
cytolytic functions in TCR~~+/CD3+ and TCR-/CD3- clones can be mediated via 
the CD2 receptor (6,29). 
I 
SCHEMATIC SUMMARY OF EVENTS INVOLVED 
IN T-CELL PROLIFERATION 
PHA, 
allostimulation 
J 
CD3/TCR antigen-receptor 
CD2-SRBC receptor 
other receptors 
I L- 2 receptor + IL-2 I c-myc I 
expression 1 expression 
? t ____ ..;_D_N_A-re_a_r_r_a_n_g-em_e_n-ts~-----"'} 
Figure 5.2 PHA or alloantigens can induce the expression of c-myc and IL-2 
receptors via the TCR~~+/CD3+ or CD2+ receptor in TCR~~+/CD2+3+ T lymphocytes, 
via the CD2+ receptor in TCR-/CD2+3- NK cells or via other receptors. 
Interaction between IL-2 with its receptor induces c-myc expression. The 
constitutively enhanced levels of IL-2 receptors and c-myc in malignant T 
cells may be a result of DNA-rearrangement(s). 
The hypothesis that signal transduction via the TCR~~+/CD3 complex 
mediates c-myc expression 
TCR~~+/CD3+ T-lymphoma cell 
was supported by the 
line JURKAT but not 
observation that the 
the other two TCR-/CD3-
T-lymphoma cell lines responded to PHA with a further increase in c-myc mRNA. 
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This PHA-induced c-myc expression also 
gene contains two promoters from 
independently (215,216). The JURKAT 
supports the suggestion that the c-myc 
which transcription can be initiated 
cell line also expresses C02 receptors 
which may be involved in c-myc expression. It is noteworthy that all three 
lymphoma .cell lines constitutively expressed c-myc at high levels in the 
absence of IL-2R. However, in malignant T cells the expression of c-myc is 
constitutively enhanced which may possibly lead to loss of IL-2R, since the 
presence of IL-2R has no longer a biological function. Recently, it has been 
observed that in human T-cell leukemias deregulation of c-myc was induced by 
DNA-rearrangements (217, 218). Reed et al. (90) showed that IL-2 can induce 
c-myc expression in cloned mouse lymphocytes. On the other hand, in human 
T-leukemia virus (HTLV-I)-infected cells the IL-2R as well as the c-myc-gene 
is permanently activated (219). 
expression in normal and malignant 
been summarized in Figure 5.2. 
Possible routes of the induction of c-myc 
TCR~~+/CD3+ and TCR-/CD3- lymphocytes have 
The results obtained for e-ras expression in normal T and NK cells 
showed a similar pattern as c-myc expression, i.e. higher levels of expression 
of e-ras were found in cloned TCR~~+/CD3+ T cells than in TCR-/CD3- NK cells 
(Table 5.4). Recently, Stevenson and Volsky (220) showed in transfection 
experiments that the expression of c-myc was stabilized when cotransfected 
into normal human lymphocytes with the ras gene. We found for TCR~~+/CD3+ T as 
well as for TCR-/CD3- NK-cell clones a positive correlation between the 
expression level of e-ras and c-myc, i.e. when c-myc mRNA levels were high 
than the e-ras mRNA levels were high and vice versa. The differences in 
proliferative capacity of TCR-/CD3- NK and TCR~~+/CD3+ T cells was reflected 
by the level of IL-2R, c-myc and e-ras expression. The higher levels of IL-2R, 
c-myc and~ mRNA in TCR~~+/CD3+ T-cell clones correlated with their higher 
proliferative capacity, i.e. the mean generation time and lifespan for 
TCR~~+/CD3+ T-cell clones being 20-28 hand 70-100 generations, respectively, 
whereas for TCR-/CD3- NK-cell clones these values are 30-40 h and 25-25 
generations (163). Moreover, the level of c-myc and e-ras mRNA correlated 
directly with the cell yield after one week of culture. 
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CHAPTER 6 
OK-432 AND IL-2 AUGMENTED CYTOTOXICITY OF HUMAN TCR-/CD3 NATURAL 
KILLER CELLS AND TCR~~+/CD3+ CYTOTOXIC T LYMPHOCYTES AT THE CLONAL LEVEL 
6.1 Introduction 
Cytotoxic T lymphocytes (CTL) directed against tumor-associated 
antigens (TAA) .can be immune specific, i.e. antigen is recognized in the 
context of major histocompatibility complex (MHC) determinants and involves 
the ~and ~chain of the T-cell receptor (TCR) (6). NK cells represent another 
immune defence system against tumor cell growth and, in contrast to CTL, exert 
MHC-unrestricted cellular cytotoxicity (CTX). It has been shown that some T 
lymphocytes also mediate MHC-unrestricted cellular cytotoxicity (CTX) after 
activation (221,222). Moreover, also lectins such as phytohaemagglutinin (PHA) 
or tumor cells can induce MHC-unrestricted CTX by immune specific T cells 
(223) and T-cell clones, (164) respectively. 
The biological response modifiers (BRM) OK-432 and interleukin-2 (IL-2) 
are used in the clinic for treatment of cancer patients. OK-432, a bacterial 
product of Streptococcus pyogenes, enhances survival of patients with lung or 
stomach cancers (93,224). IL-2 is a growth factor for human T cells and NK 
cells (210,225) and it affects the lytic capacity of these cells (96). In 
vitro, the MHC-unrestricted CTX of peripheral blood lymphocytes (PBL) against 
K562 can be enhanced by OK-432 and IL-2 (155,226-228). It is assumed that this 
effect is due to OK-432-induced IL-2 production (229). With respect to the 
cell type involved in this process there is evidence that not CTL but NK cells 
are responsive to OK-432 (100). However, this evidence has been obtained in 
experiments with fresh PBL or with T-cell and NK-cell-enriched percoll 
fractions. 
We have produced clones of various lymphocyte lineages of NK cells and 
T cells and tested the effects of OK-432 and IL-2 on the cytotoxic response of 
TCR~~+/CD3+4+;8+ CTL and TCR-/CD3-16+ NK cells at the clonal level in 
comparison to PBL of healthy individuals. 
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6.2 Materials and methods 
6.2.1 Cytotoxic effector cells 
PBL comprising CTL and NK cells, were obtained from blood of healthy 
donors by centrifugation on Ficoll-Isopaque (d=l.077 g/cm3 l. The cells were 
resuspended in RPMI medium supplemented with 10% FCS (heat-inactivated), 4 mM 
glutamin and antibiotics. TCR-/CD3 NK-cell clones and TCR~~+/CD3+ CTL clones 
used are summarized in Table 6.1. NK-cell clones were obtained by limiting 
dilution of PBL without prior activation against stimulator cells. TCR~~+/CD3 
CTL clones were obtained by limiting dilution of PBL after stimulation with 
Epstein-Barr virus (EBV) transformed lymphoblastoid B-cell lines (B-LCL) 
(167). Cloned cells were cultured as described previously (163). Briefly, 
responder cells (2x103 cells/200 ~l) were cultured in RPMI medium supplemented 
with 10% human serum (not heat-inactivated), 4 mM glutamin, 1 ~g/ml 
indomethacin, 1 ~g leucoagglutinin/ml or not, 2s·u recombinant IL-2/ml and 
antibiotics. Gamma-irradiated (20 Gy) EBV transformed B-LCL 5x104 cells/200 
~l) and y-irradiated (20Gy) allogeneic lymphocytes (10 5 ce1ls/200 ~1) were 
added as feeder cells. 
TABLE 6.1 
CLONED EFFECTOR CELLS 
effector phenotype MHC target cells 
cells CD2 CD3 CD4 CDS CD16 
------
spec CTX 
TCR-/CD3 NK clones 
NK76* + + no K562 Daudi P815-IgG*** 
NK77* + + no K562 Daudi P815-IgG 
NK472** + + no K562 Daudi P815-IgG 
NK468** + + no K562 Daudi P815-IgG 
NK436** + + no K562 Daudi P815-IgG 
TCR~~+/CD3+ CTL clones 
CTLll + + + no K562 
CTLll + + + class I BSM 
CTL9 + + + Cw3, class I BSM 
CTL20 + + + Drw6, class II APD Daudi 
* NK-cell clones derived from a patient with Ty-lymphocytosis 
** NK-cell clones derived from a SCID (severe combined immunodeficiency 
disease) patient. 
***ADCC 
All CTL clones are derived from healthy individuals 
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6.2.2 Target cells 
The target cells used are detailed in Table 6.2. These cell lines are 
cultured in RPMI medium supplemented with 10% FCS (heat-inactivated), 2 mM 
glutamin and antibiotics. 
human 
tumor cell lines 
K562 
Daudi 
BSM 
APD 
mouse tumor 
cell line 
P815* 
TABLE 6.2 
TARGET CELLS 
expression of 
target MHC antigens 
no 
Drw6 
Cw3 
Drw6 
no 
erythroid leukemia 
Burkitt lymphoma 
EBV transformed B-LCL 
EBV transformed B-LCL 
mastocytoma cell line 
* P815 mouse cells coated with anti-P815 antiserum (IgG) were 
used for the antibody-dependent cellular cytotoxicity (ADCC) 
6.2.3 BRM treatment of effector cells 
OK-432, a lyophilized powder of penicillin-treated low virulent 
Streptococcus pyogenes was kindly provided by Chugai Pharmaceutical Co., 
Tokyo, Japan. Exposure of effector cells with OK-432 has been described in 
detail previously (155,227). Briefly, effector cells (10 6 /ml) were resuspended 
in RPMI medium supplemented with 10% FCS (heat-inactivated), 4 mM glutamin, 
antibiotics and various concentrations of OK-432 at 37°C. Cells were incubated 
with OK-432 in a plastic tube (Falcon 2058) for different time periods. 
Thereafter, 
CTX. Human 
Switzerland. 
the cells were washed, resuspended in RPMI medium and tested for 
recombinant IL-2 (105 U/ml) was a gift from Biogen, Geneva, 
IL-2 was diluted and used at a final concentration of 25 U/ml. 
Effector cells were incubated with IL-2 for 20 h in microtiter plates 
85 
(Greiner) at 37°C. Then, target cells were added to the wells of the 
microtiter plate and CTX was determined. 
6.2.4. Determination of cytotoxic activity 
CTX was determined in a 51 Cr-release assay in round-bottom microtiter 
plates as described earlier (164). Briefly, varying cell numbers in 150 ~1 
RPM! medium supplemented with 10% FCS (heat-inactivated), 2 mM glutamin and 
antibiotics, were seeded in the wells of the microtiter plate before the 
addition of 100 pl of 103 51 Cr-labelled target cells. Cells were incubated for 
3 h at 37°C and centrifuged. Supernatant (100 pl) was collected and 
radioactivity was determined. Specific 51 Cr-release was calculated as: 
experiment cpm - spontaneous cpm 
X 100% 
maximum cpm - spontaneous cpm 
The maximum 51 Cr-release was obtained by incubation of the target cells 
with 10% (v/v) Triton X-100. Statistical significances of differences were 
calculated from the cpm values of triplicate samples by Student t-test. 
6.3 Results 
6.3.1 OK-432 effect on fresh PBL 
Optimal concentration and incubation time of OK-432 appeared to be 0.5 
Klinische Einheiten (KE) OK-432/ml and 20 h, respectively (155,227). The 
OK-432 effect on the level of CTX by PBL of various healthy donors against 
NK-susceptible K562 and NK-resistent Daudi target cells and of antibody 
dependent cellular cytotoxicity (ADCC) using P815-IgG target cells was 
determined. OK-432-treated PBL showed significantly higher CTX against K562 
target cells than untreated PBL, i.e. 6 out of 9 donors responded positively 
to OK-432 (Table 6.3). When Daudi cells were used as targets, OK-432 augmented 
the CTX of PBL for all 9 donors tested (Table 6.3). 
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donor number 
Fresh 
PBL 
1 
2 
3 
4 
5 
6 
7 
8 
9 
TABLE 6.3 
OK-432 AUGMENTED CTX BY FRESH PBL 
percent lysis of target cells* 
K562 
OK-432 
+ 
27 54** 
36 52** 
14 23** 
32 52** 
27 44** 
29 30 
31 28 
27 44** 
29 30 
Daudi 
OK-432 
+ 
12 29** 
17 45** 
8 15** 
9 29** 
13 29** 
9 27** 
17 30** 
15 28** 
22 42** 
* Results expressed as percent 51 Cr-release; effector:target 
ratio 27:1 
** Significantly higher than control cytotoxicity (p<0.05) 
PBL of 7 out of 12 donors showed OK-432-augmented ADCC (P815 cells 
coated with IgG) but not of uncoated (control) P815 target cells (Table 6.4). 
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donor number 
fresh 
PBL 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
TABLE 6.4 
OK-432 AUGMENTED ADCC BY FRESH PBL 
percent lysis of target cells* 
P815 
OK-432 
+ 
7 15 
0 1 
0 1 
0 0 
3 4 
0 4 
0 3 
0 1 
0 3 
0 0 
0 3 
3 6 
P815-IgG 
OK-432 
+ 
52 72** 
46 57** 
14 25** 
34 53** 
47 52 
37 37 
28 33 
25 30 
48 so 
29 47** 
39 56** 
38 51** 
* Results expressed as percent 51 Cr-release; effector:target 
27:1 
** Significantly higher than control CTX (p<O.OS) 
6.3.2 OK-432 effect on TCR-/CD3- cloned NK cells 
Optimal concentration and incubation time of OK-432 were determined for 
cloned NK cells. Effector cells were incubated with 0, 0.01, 0.1, 0.5 and 1 KE 
OK-432/ml for 8, 16 and 20 h. Similar to fresh PBL, incubation with 0.5 KE 
OK-432 for 20 h appeared to the optimal for cultured NK-cell clones (Fig. 
6.1). 
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Figure 6.1: Optimal concentration of OK-432 and incubation time for cloned 
TCR-/CD3- NK cells. 1A: cells were incubated for 20 h with 0, 0.01, 0.1, 0.5 
and 1 KE OK-432/ml; 1B: cells were incubated for 8, 16 and 20 h with 0.5 KE 
OK-432/ml. Effector cell: clone NK76; target cell: Daudi. 
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Five NK-cell clones (NK76, NK77, NK436, NK468 and NK472) were incubated 
with and without OK-432. Subsequently, the CTX against K562 and Daudi target 
cells as well as the ADCC was determined. As shown in Table 6.5 the 
MHC-unrestricted CTX is increased by OK7 432 using K562 and Daudi target cells, 
provided the effector cells were cultured without PHA (Table 6.5, Fig. 6.2). 
TABLE 6.5 
INFLUENCE OF PHA ON OK-432 RESPONSIVENESS OF 
CLONED TCR-/CD3- NK CELLS 
effector cells percent lysis of target cells* 
NK clones*** 
NK76 
NK76 
NK77 
NK77 
PHA K562 Daudi 
OK-432 
P815 
OK-432 
+ 
+ 
OK-432 
+ + 
34 45** 25 32** 0 
56 54 48 46 5 
34 56** 52 
63 63 44 
66** nd 
51 nd 
+ 
3 
5 
nd 
nd 
P815-IgG 
OK-432 
+ 
33 46** 
38 49** 
57 
55 
69** 
60 
* Results expressed as percent 51 Cr-release: effector:target 
ratio 27:1 (NK cells against all target cells) 
** Significantly higher than control cytotoxicity (p<0.05) 
*** NK-cell clones were cultured with and without PHA 
nd: not done 
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Figure 6.2: OK-432 does not affect CTX of PHA cultures of TCR-/CD3- NK-cell 
clones; cloned NK cells were incubated for 20 h with 0.5 KE OK-432/ml. 
Effector cell: clone NK77; target cell: K562. 
Moreover, in some experiments PHA inhibited the OK-432 response of 
cultured NK cells (Table 6.5). A complicating factor in the above mentioned 
relationship between OK-432 augmentation of NK-cell CTX and PHA is the 
influence of the proliferative capacity of these effector cells, i.e., only 
NK-cell clones with a cell yield higher than about 1000% after 1 week of 
culture responded to OK-432 with augmented CTX (Table 6.6). Indeed, the 2 
NK-cell clones (NK76 and NK77) with a high proliferative capacity and cultured 
without PHA showed enhanced lytic activity. Vhen the cell yield of clone NK76 
was higher than about 900%, significantly augmented cytolysis of K562 and 
Daudi target cells was observed. Vith clone NK77, such a response was found 
when the cell yield was higher than 700%. This "growth dependency" of OK-432 
responsiveness of clones NK76 and NK77 could not be demonstrated for the ADCC 
(Table 6.6). 
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TABLE 6.6 
EFFECT OF OK-432 ON CTX OF TCR-/CD3- NK CELL 
CLONES IN RELATION TO PROLIFERATION 
NK cell percent of percent lysis of target cells* 
clones**** cell yield K562 Daudi P815-IgG 
OK-432 OK-432 OK-432 
+ + + 
NK76 
exp.1 833 46 42 50 52 35 33 
exp.2 892 31 39 23 28 42 28*** 
exp.3 1600 2 11** 8 25** 9 26** 
exp.4 1760 36 49** 55 67** nd nd 
exp.5 1932 8 39** 17 44** 13 27 
exp.6 2300 28 41** 49 67** 30 31 
NK77 
exp.1 585 53 57 54 44 37 29 
exp.2 700 57 41 37 41 54 36*** 
exp.3 700 32 40 31 45** 29 23 
exp.4 1389 12 39** 12 39** 43 59** 
exp.5 1133 58 73** 46 56** nd nd 
exp.6 1833 27 58** 26 67** 15 24** 
exp.7 6000 46 61** 52 62** 26 25 
* Results expressed as percent 51 Cr-release; effector:target 9:1 
** Significantly higher than control CTX (p<0.05) 
*** Significantly lower than control CTX (p<O.OS) 
**** NK-cell clones were cultured without PHA 
nd: not done 
Clones NK436, NK468 and NK472 did not respond 
(data not shown) when cultured in the presence of PHA. 
NK-cell clones do not proliferate. 
positively to OK-432 
Without PHA, these 
6.3.3 OK-432 effect on cloned TCR~+/CD3+ CTL 
As for NK-cell clones and PBL, optimal concentration and incubation time of 
OK-432 appeared to be 0.5 KE/ml and 20 h, respectively (not shown). Five 
T-cell clones, 3 of which were cytolytic (CTL9, CTL20 and CTL11) and 2 
noncytolytic (clone 317 and clone 397), were incubated with and without 
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OK-432. Subsequently, the CTX against K562, Daudi, APD and BSM target cells 
was determined. OK-432 augmented the CTX of MHC class !-specific cloned CTL9 
(CD3+8+) and of clone CTL11 (CD3+8+) using BSM target cells (MHC class r+ and 
II+) (Table 6.7). Using Daudi (MHC class r+and II+) and APD (MHC class I+ and 
II+) as target cells the CTX of MHC class II specific CTL20 (CD3+4+) was not 
affected by OK-432 (Table 6.7). 
TABLE 6.7 
OK-432 AUGMENTED CTX OF TCR~a+/CD3+8+ BUT NOT OF 
TCR~a+/CD3+4+ T CELL CLONES 
effector cells percent lysis of target cells* 
K562 Daudi BSM/APD 
CTL clones**** OK-432 OK-432 OK-432 
+ + + 
CTLll (CD3+8+) 31 19*** 1 1 35 54** 
CTL9 (CD3+8+) 2 5 0 0 38 49** 
CTL20 (CD3+4+) 12 16 55 55 36 40 
* Results expressed as percent 51 Cr-release; effector:target 
ratio 81:1 (K562 and Daudi target cells) and 3:1 (BSM/APD 
target cells) 
** Significantly higher than control CTX (p<0.05) 
*** Significantly lower than control CTX (p<0.05) 
****All CTL clones were cultured with PHA 
Clones CTL9 and CTL20 did not lyse K562 cells, neither in the presence 
nor in the absence of OK-432. OK-432 inhibited the lysis of K562 target cells 
by clone CTL11 (Table 6.7). In contrast to the situation with NK cells, 
OK-432-induced CTX by none of the cloned T cells used was affected by PHA 
(data not shown). OK-432 was not able to induce CTX in the non-cytolytic 
clones 317 and 397 (data not shown). 
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6.3.4 Comparison of OK-432 and IL-2 effects on cloned TCR-/CD3 NK cells 
and TCR«~+/CD3+ CTL 
OK-432 and IL-2 were compared for their effects on CTX and ADCC of PBL, 
or cloned NK cells and T cells. PBL stimulated with OK-432 or IL-2 showed 
augmented cytolysis of K562 target cells while the ADCC was only augmented by 
OK-432 and not by IL-2. In these experiments, IL-2R were not expressed on the 
effector cells after stimulation with OK-432 or IL-2 (Table 6.8). 
TABLE 6.8 
OK-432 AND IL-2 AUGMENTS THE CTX OF FRESH PBL WHILE IL-2R 
healthy 
donor 
1713 
1714 
1634 
WERE NOT DETECTED AFTER STIMULATION 
stimulation 
untreated 
OK-432 
IL-2 
PHA 
untreated 
OK-432 
IL-2 
PHA 
untreated 
OK-432 
IL-2 
PHA 
percent of 
IL-2R 
9 
11 
8 
so 
10 
7 
7 
34 
6 
8 
5 
54 
percent of lysis of target 
cells* 
K562 P815 P815-IgG 
30 0 29 
47** 0 47** 
42** 0 35 
nd nd nd 
38 0 39 
53** 3 56** 
53** 0 48 
nd nd nd 
21 3 38 
40** 6 51** 
33** 3 44 
nd nd nd 
* Results expressed as percent 51 Cr-release; effector:target 
ratio 27:1 
** Significantly higher than control CTX (p<O.OS) 
With respect toNK cells, OK-432 and IL-2 augmented the CTX of NK-cell 
clones NK76 and NK77 against K562 and Daudi target cells. In contrast to 
OK-432, IL-2 never augmented the ADCC of NK-cell clones NK76 and NK77. The 
apparently augmented ADCC by IL-2-treated NK-cell clone NK77, as shown in 
Table 6.9, was due to the induction of CTX against uncoated P815 cells 
(control). As for OK-432, IL-2 did not further enhance the CTX of clones 
cultured in medium plus PHA. No correlation between IL-2 responsiveness and 
the proliferative capacity of NK-cell clones was observed (data not shown). 
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The effects of OK-432 and IL-2 were also compared for the T-cell 
clones (Table 6.9). OK-432 and IL-2 could not induce cytolysis of K562 target 
cells by the clones CTL9 and CTL20 but IL-2 augmented the CTX of clone CTL11 
against K562 target cells. Using BSM as target cells, both OK-432 and IL-2 
augmented the CTX of clone CTL9 and CTL11 (Table 6.9). Unlike OK-432, IL-2 
augmented the CTX of clone CTL20 against Daudi and APD stimulator cells. 
TABLE 6.9 
EFFECTS OF OK-432 AND IL-2 ON THE CTX OF TCR-/CD3 
NK CELL CLONES AND TCRcxf3+ /CD3+ T CELL CLONES 
percent lysis of target cells* 
exp. 1 exp.2 
effector cells target cells OK-432 IL-2 
+ + 
NK clones**** 
NK76 K562 27 49** 4 41** 
Daudi 23 47** 1 24** 
P815-IgG 21 53 36 38 
P815 1 2 0 1 
NK77 K562 12 39** 18 32** 
· Daudi 12 39** 12 49** 
P815-IgG 32 42** 19 43** 
P815 0 2 0 27** 
CTL clones***** 
CTLll K562 31 19*** 8 38** 
Daudi 1 1 0 0 
BSM 34 54** 26 62** 
CTL9 K562 5 2 3 6 
Daudi 0 0 1 4 
BSM 38 49** 22 34** 
CTL20 K562 9 7 13 18 
Daudi 23 26 20 43** 
APD 45 42 20 43** 
* Results expressed as percent 51 Cr-release; effector:target 
ratio 9:1 (NK-cell clones against all target cells), 81:1 
(CTL clones against K562 and Daudi target cells) and 3:1 (CTL 
clones against BSM and APD target cells). 
** Significantly higher than control CTX (p<O.OS) 
*** Significantly lower than control CTX (p<O.OS) 
**** NK-cell clones were cultured without PHA 
*****CTL clones were cultured with PHA 
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6.4 Discussion 
BRM are defined as cell products that modify the hosts biological 
response. BRM can affect the immune system by activation, increase or 
restoration of reactivity of various immune effector mechanisms, or by 
inhibition or abrogation of cellular functions resulting in reduced immune 
responsiveness. Among the immunopotentiating BRM, 
effective bacterial product for cancer therapy (99). 
fresh PBL with OK-432 augments the MHC-unrestricted 
OK-432 is known as an 
In vitro stimulation of 
CTX (155,227). In this 
chapter we show that with fresh PBL obtained from various healthy donors the 
MHC-unrestricted CTX was augmented by OK-432 but its level is donor dependent 
(Table 6.3). Several donors were repeatedly tested and results for individual 
donors were reproducable (230). 
We have cloned TCR-/CD3 NK cells and TCR~~+/CD3+ CTL (134,163,167) to 
see whether both cell types respond to OK-432 and IL-2. OK-432 augmented the 
MHC-unrestricted cytolysis of NK-cell clones as well as fresh PBL. However, we 
demonstrated that several requirements have to be met to allow for 
augmentation of cytolysis by OK-432. First, when cloned mz cells were grown in 
medium plus PHA they already showed increased lytic activity, which could not 
be further enhanced by OK-432. This may well depend on the fact that the 
action of PHA involves the production of IL-2 by the effector or feeder cells 
which in turn augments the CTX. These results are supported by the observation 
that in parallel experiments PHA cultures of NK-cell clones had a higher level 
of CTX than those cultured without PHA (Table 6.5). Secondly, CTX of only 
those m<-cell clones (NK76 and NK77) with a good proliferative capacity (Table 
6.6) was augmented by OK-432. The other NK-cell clones studied, NK436, NK468 
and m<472 do not proliferate without PHA. It has been reported that OK-432 
does not enhance the ADCC (231). Interestingly, PBL and (less frequently) 
cloned NK cells exerted increased ADCC after stimulation with OK-432 but not 
with IL-2 (Table 6.8 and 6.9), even when 100 or 1000 U recombinant IL-2/ml was 
used (data not shown). In contrast to the idea that OK-432-augmented CTX might 
occur via IL-2 production, these results suggest that OK-432 stimulation of 
ADCC is IL-2 independent. In addition, if OK-432 augments the CTX via IL-2 
production, expression of IL-2 receptors on fresh PBL should be required for 
action of both BRM. Surprisingly, using anti-TAC monoclonal antibodies (mAb) 
expression of IL-2 receptors was not observed on OK-432 and IL-2-stimulated 
PBL (Table 6.8). Stimulation of fresh PBL or cloned NK cells with IL-2 and 
OK-432 in the presence of anti-TAC mAb did not show the expected inhibition of 
NK-cell activity (data not shown). Recently, NK cells has been reported with 
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the IL-2R ~chain (56). Anti-TAG mAb only interacts with the IL-2R ~-chain 
(see chapter 1, section 1.6). This may explain the above mentioned results 
i.e. the inability to detect IL-2 receptors and the inability to inhibit the 
IL-2-induced NK-cell activity using anti-TAG Mab. Preliminary results indicate 
that OK-432 binds to the IgG-Fc receptor, among other membrane structures. 
Thus, augmentation of the ADGG by OK-432, which involves the IgG-Fc receptor 
(34) suggests that these IgG-Fc receptors function as an activation site for 
OK-432 stimulation. We indeed showed that human IgG-Fc receptors can transduce 
activation signals for induction of GTX (27). 
We also found that OK-432 can occasionally enhance the GTX of GTL 
(GD3+8+), i.e. OK-432-augmented GTX by the MHG-restricted GD3+s+ T-cell clones 
GTL11 and GTL9 using BSM target cells (MHG class r+ and II+). It is possible 
that these BRM enhance the MHG-specific component of GTX by GTL since neither 
the lysis by either MHG negative target cells nor target cells with MHG 
incompatible determinants were lysed (Table 6.9). Results obtained with Gw3+ 
lymphocytes as target cells indeed showed IL-2-induced augmentation of the 
MHG-specific component (Gw3) of GTL9 (data not shown). The MHG class 
!!-restricted cloned GD3+,4+ GTL20 cells were not activated by OK-432. As yet, 
too few clones have been tested to prove that the observed differences in the 
OK-432-induced lytic response by class I and !!-restricted cytotoxic T-cell 
clones are real. 
In conclusion, cloned TGR-/GD3- NK cells as well as cloned TGR~~+/GD3+ 
GTL can respond to OK-432 and IL-2. For both types of cells it appeared that 
not all clones responded positively to the BRM. With respect toNK cells, the 
proliferative capacity of these clones may play a role in their responsiveness 
to OK-432 and IL-2. The OK-432 unresponsiveness of some T-cell clones remains 
to be elucidated. With respect to its mechanism, our results indicate that 
OK-432 acts independently of IL-2. 
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CHAPTER 7 
SUMMARY AND GENERAL DISCUSSION 
Since 1909 when the concept of immunosurveillance of tumor cells was 
proposed by Ehrlich (232) for the first time, many investigators focused on 
the isolation and identification of lymphoid effector cells expressing 
antitumor activity. The aim was to use these as immunotherapeutic tools. 
During the sixties and early seventies it became clear that cytotoxic T 
lymphocytes (CTL), natural killer (NK) cells and monocytes/macrophages, alone 
in sequence or in concert with other cell types exerted antitumor activity 
(1,2,233-235). During the late seventies cloning of lymphoid effector cells 
with antitumor reactivity (33,183-185) enabled the study of pure 
effector-target cell interactions, which revealed in the eighties information 
as to how the immune response could be manipulated. Now, at the end of the 
eighties it is clear that the cellular interactions and the involvement of 
numerous soluble factors in the immune response against tumors are more 
complex than anticipated from the earlier in vitro experiments. This thesis 
describes approaches how to potentiate lymphoid killer activities against 
tumors. First, target cell susceptibility to lysis and effector cell 
specificity has been studied using freshly isolated and cultured tumor cells 
as targets. Second, T-cell regulation in cancer patients has been investigated 
in vitro. Third, lytic activity of T-cell receptor negative (TCR-)/CD3- NK and 
TCR~~+/CD3+ T cells has been modulated by interleukin-2 (IL-2) and OK-432. 
Fourth, (cytotoxic) lymphocytes have been immortalized by somatic cell 
hybridization to sustain their function, and finally expression of 
proto-oncogenes and IL-2R in resting and activated normal and malignant T 
cells has been studied. 
7.1 Cytotoxic lymphocytes with antitumor activity: target cell 
susceptibility and effector cell specificity 
Following the appearance of tumor cells in a host, a cascade of immune 
reactions is initiated involving different types of immune cells culminating 
in the generation of cytotoxic lymphocytes that destroy the tumor. At first, 
TCR~~+/CD3+ CTL were considered as the sole effector cell type able to lyse 
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target cells (1,2) but later also TCR-/CD3 NK cells were found to kill cells 
(233-235). Recently, a third type of cytotoxic lymphocytes has been isolated, 
termed TCRyS+/CD3+ lymphocytes. The latter share features with TCR~~+/CD3+ 
lymphocytes as well as with TCR-/CD3 NK lymphocytes. While TCR~~+/CD3+ 
lymphocytes and TCR-/CD3 NK cells are known to exert antitumor activity, it 
is still unclear whether TCRyS+/CD3+ lymphocytes can also be involved in 
antitumor responses. Several authors have suggested that TCRyS+/CD3+ cells are 
involved in the immune response against viral or bacterial infections 
(132,161,165). In chapter 2 of this thesis evidence is provided that each of 
these three lymphocyte populations can lyse cultured as well as freshly 
isolated tumor cells. Moreover, the efficacy of lysis by TCRyS+/CD3+ clones 
was generally as high as that of TCR-/CD3 NK lymphocytes. TCRyS+/CD3+ clones 
were able to lyse target cells, in a 
From the results described 
(37,38,41,43) the following picture 
MHC-unrestricted fashion. 
in chapter 2 and from literature data 
emerges. When TCR~~+/CD3+ lymphocytes 
encounter tumor cells in vivo, the sequence of events include: (1) conjugation 
to the target cell; (2) T-cell activation; (3) triggering and delivery of a 
lethal hit; and (4) lysis of the tumor cell. After effector-target cell 
conjugation, the effector cell will be triggered via the TCR~~+/CD3 complex on 
the cell membrane (antigen recognition and signal transduction), which 
initiates production of IL-2 and expression of IL-2 receptors, and subsequent 
proliferation and/or lysis. Upon activation, and delivery of the lethal hit 
the CTL detaches from the tumor cells and subsequently may recycle. Activation 
of TCR~~+/CD3+ lymphocytes only occurs when the tumor target cell expresses 
tumor-associated antigens (TAA) in the context of MHC determinants, i.e. 
MHC-restricted recognition and lysis. More or less the same mechanisms could 
be involved in killing by TCRyS+/CD3+ lymphocytes, although TCRyS+/CD3+ cells 
are able to recognise and lyse MHC- as well as (allogeneic) MHC+ tumor cells 
(236). In both cases, TCRyS+/CD3+ lymphocytes need to be activated, for 
instance, by IL-2, to trigger the lytic machinery (136). 
In contrast to TCR~~+/CD3+ and TCRyS+/CD3+ cells, TCR-/CD3 NK cells do 
not require prior activation to lyse tumor cells (for a review, see 6). 
Although TCR-/CD3 NK lymphocytes lyse MHc- and MHC+ target cells, MHC 
determinants appear not to be involved in the process of recognition (for a 
review, see 6). 
99 
7.2 Where does the immune system fail? The role of accessory cells 
In cancer patients, immune mechanisms have failed to destroy the tumor 
cells. The question arises is why? Are, for example, the activation and 
subsequent proliferation steps inhibited, directly or indirectly, by the tumor 
cells, or are the "end point" lytic functions blocked. With respect to 
TCR~~+/C03+ cells, the possibility should be taken into account that TAA 
and/or MHC determinants are not functionally expressed on tumor cells 
resulting in immune unresponsiveness. Results of in vitro experiments 
presented in chapter 3 of this thesis indicate that tumor cells of different 
histologic type can be recognized by autologous lymphocytes. This can be 
interpreted from the augmented levels of IL-2R+ lymphocytes among "fresh" PBL 
derived from cancer patients. Further studies revealed that C04+ lymphocytes 
(helper/inducer T cells, termed accessory cells) were preferentially activated 
by the tumor cells, i.e. an elevated proportion of C04 lymphocytes expressed 
the IL-2R in the cancer patients. The IL-2R- T cell fraction mainly comprised 
cos+ lymphocytes. The fact that we were able to activate this C04+ lymphocytes 
by in vitro stimulation with autologous tumor cells supports the idea that 
these C04+ lymphocytes were activated in vivo by the tumor cells. Apparently, 
the tumor cells of the patients express "non-self" antigens which can be 
recognized by the C04+ T cells. Failures of the immune system to destroy the 
tumor cells may result from lack of signal transduction pathways in the COS+ T 
cells. 
Results described in chapter 3 indicate that cos+ suppressor T cells 
were not activated by autologous tumor cells, neither in vivo nor in vitro. 
7.3 Potentiation of cytolytic activity of cloned lymphocytes 
Knowing which populations of cytotoxic lymphocytes can be lytic against 
tumor cells (chapter 2) and in view of the lack of an effective antitumor 
immune response in vivo (chapter 3), one strategy is to enhance existing 
cellular cytotoxicity (CTX) of lymphoid effector cells. In recent years 
considerable progress has been made towards the in vitro regulation of 
lymphocyte function using biological response modifiers (BRM) such as IL-2, 
interferon (IFN) and OK-432 (94-96,99-101,110). We have studied the 
responsiveness of lymphocytes to OK-432 and IL-2 using cloned TCR-/CD3 NK 
cells and TCR~~+/C03+ CTL. The results obtained (chapter 5 of this thesis) 
show that CTX of both TCR-/C03 NK-cell clones and TCR~~+/C03+ T-cell clones 
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was enhanced by OK-432. Similar results were found using IL-2. For both cell 
types it appeared that not all clones responded to OK-432 and IL-2. When a 
clone was noncytolytic towards a certain target cell, no CTX could be induced 
against that target by OK-432 or IL-2. Several authors suggested that 
OK-432-induced CTX occurs via the production of IL-2 (229). We found that 
antibody-dependent cellular cytotoxicity (ADCC) was enhanced by OK-432 but not 
by IL-2 (chapter 6), which indicates that augmentation of CTX by OK-432 can 
occur independently from IL-2. Preliminary results suggest that OK-432 may 
bind to the IgG-Fc-receptor (CD16) (involving the ADCC), in this respect 
Fc-receptors may function as an activation site for OK-432. Indeed, we have 
shown that human CD16 can transduce activation signals resulting in enhanced 
CTX (27). As mentioned above, not all lymphocytes (clones) responded to BRM. 
Maximal effectiveness, with respect to immunotherapy of cancer patients, may 
be obtained when the effector cells responsive to BRM are separated from 
nonresponsive cells by selective cloning or bulk culture procedures, expanded 
in vitro and reinfused into the patient. 
7.4 Immortalized 
immunotherapy 
cytotoxic lymphocytes as potential tools for 
In order to have access to unlimited numbers of cytotoxic lymphocyte 
clones for studying human effector-target cell interactions and/or for 
therapeutic purposes, permanently available, i.e. immortalized lymphocytes are 
desirable. Hybridoma technology has been applied widely and has become the 
method of choice to immortalize lymphocyte functions (139-142). Until now, 
xenogeneic (mouse-man) as well as human-human hybridomas have been produced 
using polyethyleneglycol (PEG) as the fusion agent (145-152). However, 
human-human hybridomas are difficult to expand. Chromosomal instability has 
frequently been observed, leading to cell death (147). Kaufmann et al. (144) 
reported that lysis of the tumor cell partner by the lymphocyte during the PEG 
fusion procedure is a major obstacle in producing cytotoxic T-cell hybridomas. 
We have demonstrated that the electric field-induced cell fusion 
technique, adapted for human T- and NK-cell fusions (chapter 4 of this 
thesis), is an efficient alternative for PEG induced cell fusion. The results 
obtained by electrofusion demonstrated that fusion efficiency depends on the 
characteristics of both fusion partners, i.e. the tumor cell and lymphocyte 
type. Microscopic observation learned that in an electrical field the tumor 
fusion partners were not lysed by the cytotoxic lymphocytes. However, in 
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contrast to the results of Kaufmann et al. (144), our data on PEG fusion do 
not suggest that there is a relationship between the presence of CTX of the T 
lymphocytes against the tumor fusion partner and the yield of hybridomas 
(chapter 4). 
Although we were able to produce 600 human-mouse and human-human 
hybridomas by PEG and electrofusion, the CTX of the obtained hybridomas 
appeared to be transient. In this respect, chromosomal instability in 
human-human as well as in human-mouse hybridomas appeared to be the causative 
factor (see chapter 4 of this thesis). As reviewed in section 1.5 of chapter 1 
the different steps of recognition, signal transduction and induction of CTX 
are all required for a successful target-cell lysis. Failure of only one of 
these steps will not allow the generation of lytic ability. The likely loss of 
chromosomes containing at least one or more genes involved in these steps 
explain our low success rate in the production of human cytotoxic lymphocyte 
hybridomas. However, our results show that PEG fusion, and in particular 
electrofusion, are efficient tools to produce human T- and NK-cell hybridomas. 
Unfortunately, somatic cell hybridization did not appear to be the most 
suitable tool for immortalizing the lytic functions. The transfer of genes 
involved in cell proliferation into cytotoxic lymphocytes appears to be more 
promising. 
7.5 Genes involved in cell proliferation 
Transfection of genes involved in cell proliferation could be an 
alternative strategy to immortalize human cytotoxic lymphocytes. Results from 
such experiments suggest that the transition from primary cells to fully 
transformed ones requires functional complementation between several gene 
involved in cell proliferation (220,237,238). Primary rodent cells were 
efficiently immortalized by transfection with cloned viral genes, e.g. 
v-Ha-ras plus v-myc, v-fos, polyoma large T-antigen gene and adenovirus, or by 
overexpressed cellular oncogenes such as c-Ha-ras and P53 (202-204,239-242). 
For immortalization of human cytotoxic lymphocytes myc and ras were considered 
suitable candidates. In addition, the genes encoding for IL-2R seemed useful 
in combination with oncogenes to immortalize human cytotoxic lymphocytes. 
We studied the expression of c-myc and e-ras proto-oncogenes at the mRNA 
level in relation to IL-2R expression, using normal human resting and 
activated TCR~~+/CD3+ T cells, NK cells and human T-lymphoma cells. C-myc was 
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found to be permanently expressed in human T-lymphoma cell lines but only 
transient in normal TCR~e+/CD3+ T and TCR-/CD3 NK cells after PHA-stimulation 
(chapter 5 of this thesis). Interestingly, the c-myc and e-ras mRNA levels 
were 10-fold higher in TCR~e+/CD3+ T cells than in TCR-/CD3 NK cells. In 
general, a positive correlation was found between proliferative capacity of 
the cytotoxic lymphocytes and c-myc oncogene mRNA levels. Stevenson and Volsky 
showed that in transfection experiments using human lymphocytes, the 
expression of v-myc was stabilized when cotransfected with the v-ras gene 
(220). We found a positive correlation between the levels of e-ras and c-myc 
mRNA, i.e. when c-myc mRNA levels were high, the e-ras mRNA levels were also 
high and vice versa. However, very recently it has been found that 
transfection of both genes on one vector in normal human lymphocytes is not 
sufficient for the induction of unlimited cell proliferation (220). These 
results suggest that still other genes are required for continuous cell 
proliferation. We (chapter 5 of this thesis) and others (243) have found that 
TCR~e+/CD3+ T cells expressed a two-fold higher level of IL-2R than TCR-/CD3-
NK cells, which correlates with their proliferative capacity. Krenke et al. 
(244) found that c-myc mRNA levels can be augmented by addition of IL-2. 
Interestingly, T 
absence of IL-2R 
lymphoma cell lines permanently 
(chapter 5 of this thesis). If 
induction of c-myc expression in normal cells, 
apparently express c-myc permanently, would not need 
Another recent report by Abken et al. 
expressed c-myc in the 
IL-2 is required for the 
T lymphoma cells, which 
IL-2R. 
(245) describes the 
immortalization of human lymphocytes by fusion of cytoplasts from mouse 1929 
cells with normal human lymphocytes using dextran as the transfection agent. 
This is the first report ever in which the successful immortalization of human 
lymphocytes is described. Abken et al. concluded that the immortalizing DNA 
was located on extrachromosomal DNA (but not on mitochondrial DNA) which 
frequently occurs in the cytoplasm of tumor cells. The immortalized 
lymphocytes contained about 10-fold more c-Ha-ras and c-myc mRNA (245), and 
6-fold more P53 mRNA than normal cells. In the future, fusion of cytoplasts 
from immortalized cells, for instance from T-lymphoma cells, with cytotoxic 
lymphocytes may be an efficient way to immortalize cytotoxic lymphocytes. 
However, transfection of oncogenes (e-ras, c-myc and P53) combined with IL-2R 
genes may also be considered. 
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7.6 Recapitulation and conclusions 
The purpose of the work described in this thesis was (1) to study the 
effector cell types involved in antitumor responses; (2) to investigate 
whether of the immune system in cancer patient may occur at tumor-target or at 
lymphocyte-effector cell level; and (3) to explore new strategies for 
producing tools for immunotherapy of cancer, i.e. enhancement of cytotoxic 
activity to optimal levels by BRM, and production of immortalized cytotoxic 
lymphocytes with stable lytic functions. 
The major conclusions that can be drawn from the results obtained are the 
following: 
1. From the three lymphoid (sub) populations studied i.e. TCR-/CD3- NK, 
TCRa~+/CD3+ and TCRyo+/CD3+ CTL clones, TCRyo+/CD3+, TCRa~+/CD3+ CTL 
appeared to have the widest target cell spectrum and to exert the 
highest level of CTX against fresh tumor cells. 
2. The failure of the immune system in the cancer patients we studied 
seems located at the level of the CDS+ lymphocyte, possibly tumor cell 
induced. This may be due to a defective signal transduction mechanism. 
3. Cytolytic activity of TCR-/CD3- NK and TCRa~+/CD3+ T-cell clones 
against tumor cells can be successfully enhanced, i.e. lymphocyte 
clones that were already active could be stimulated further by OK-432 
and IL-2. 
4. In an attempt to immortalize cytotoxic lymphocytes by somatic cell 
hybridization, an efficient electrofusion system was developed for the 
first time, allowing to produce T- and NK-cell hybridomas routinely. In 
spite of the large number of hybridomas generated, only a few were 
transiently cytolytic. This is most likely due to chromosomal 
instability of the hybridomas. As suggested by our studies and those of 
others, DNA-mediated transfer of multiple genes, for instance e-ras, 
c-myc, PS3 and the IL-2R gene, involved in cell differentiation and 
proliferation may be an alternative strategy to immortalize cytotoxic 
lymphocytes. 
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SAMENVATTING 
Dit proefschrift beschrijft het mobiliseren van cytotoxische lymfocyten 
met als einddoel immuuntherapie van kanker. Cytotoxische lymfocyten vormen de 
laatste schakel in een keten van cellulaire immuun systeem interakties. De 
meest voorkomende typen zijn TCRa~+/CD3+4+ cytotoxische T-lymfocyten (CTL), 
TCRa~+/CD3+a+ CTL, TCRy&+/CD3+ CTL, en TCR-/CD3- "natural killer" (NK) cellen. 
Tegen het einde van de jaren zestig werd duidelijk dat TCRa~+/CD3+ CTL 
en TCR-/CD3- NK cellen betrokken zijn bij de immuunrespons tegen tumoren. 
Echter, zoals beschreven in hoofdstuk 2 van dit proefschrift zijn ook 
TCRy&+/CD3+ in staat gekweekte en zelfs "vers" geisoleerde tumorcellen te 
lyseren in vitro. De lytische capaciteit van gekloneerde TCRyo+/CD3+ CTL bleek 
soms zelfs hoger te zijn dan die van gekloneerde TCR-/CD3- NK cellen. 
Het feit dat er ondanks de aanwezigheid van cytotoxische lymfocyten 
toch tumoren in het menselijk lichaam onstaan kan verschillende oorzaken 
hebben. Ergens in de keten van cellulaire interakties, die uiteindelijk de 
cytotoxische cellen tot aktiviteit aanzet kan een verstoring optreden, hetzij 
doordat een of meerdere cellulaire funkties geremd worden, hetzij doordat de 
vermeerdering van een bepaald celtype geremd wordt. Ook is het mogelijk dat de 
tumor niet in staat is een immuunrespons op te wekken omdat 
tumor-geassocieerde antigenen (TAA) niet herkend kunnen worden, bijvoorbeeld 
omdat ze niet in voldoende mate aanwezig zijn, of door de lage frequentie of 
afwezigheid van zogenaamde "major histocompatibility" (MHC) determinanten. MHC 
determinanten zijn een voorwaarde om de CTL te aktiveren. Tenslotte is het ook 
nog mogelijk dat strukturen voor de niet-antigeen specifieke cel-adhesie, de 
zogenaamde ligand, in onvoldoende mate of in gemuteerde vorm aanwezig zijn op 
de tumorcel waardoor effektor-doelwitcel interakties niet tot stand kunnen 
komen. 
Verhoogde percentages van interleukine-2 (IL-2) receptor positieve (R+) 
cellen in het perifere bloed van kanker patienten (11-29%) in vergelijking met 
gezonde donoren (0-10%) deed vermoeden dat de tumoren van deze patienten 
immunogeen zijn (Hoofdstuk 3). Uit de analyse van membraanantigenen met behulp 
van monok1ona1e anti1ichamen (mAb) bleek dat de IL-2R+ cellen voornamelijk 
CD4+ lymfocyten waren. De in vitro stimulatie van perifere bloed lymfocyten 
(PBL) van deze patienten met autologe tumorcellen, gaf ook preferente 
stimulatie van de CD4+ lymfocyten. 
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In tegenstelling tot C04+ lymfocyten bleken cos+ lymfocyten niet te 
reageren op stimulatie met autologe tumorcellen; er werd geen toename van 
IL-2R gevonden op "verse" cos+ lymfocyten uit het bloed van kankerpatienten. 
Evenmin kon in vitro de lytische aktiviteit en proliferatie van deze cos+ 
lymfocyten geinduceerd worden met autologe tumorcellen. 
Het onderzoek beschreven in Hoofdstuk 2 geeft aldus aanleiding tot de 
konklusie dat tumoren in vitro en waarschijnlijk ook in vivo IL-ZR kunnen 
induceren op autologe C04+ lymfocyten. Het onvermogen van cos+ lymfocyten om 
te reageren op autologe tumorcellen in vivo en in vitro zou een verklaring 
kunnen zijn voor de afwezigheid van lytische aktiviteit van de T-cellen tegen 
de autologe tumor. 
Eind 1970 werd het mogelijk effektor cellen te kloneren in vitro en ze 
te vermeerderen in speciaal ontwikkelde kweeksystemen. Hierbij worden de 
lymfocyten gestimuleerd met allo-antigenen, mitogenen en/of IL-2. Gekloneerde 
lymfoide effektor cellen werden door ons gebruikt om effektor-doelwitcel 
interakties te bestuderen. 
Voor biochemische alswel celbiologische studies bleken de aantallen 
cellen verkregen met behulp van de daartoe bestemde expansiesystemen 
onvoldoende. In hoofdstuk 4 wordt de immortalisatie van cytotoxische 
lymfocyten door middel van somatische celfusie beschreven. Cytotoxische 
lymfocyten werden met behulp van polyethyleen glycol (PEG) gefuseerd met 
tumorcellen, met als doel de onbeperkte proliferatieve kapaciteit van de 
tumorcel over te dragen op de cytotoxische lymfocyt met behoud van diens 
lytische funktie. Zeven verschillende humane T-lymfoma cellijnen en twee 
verschillende muize myeloom cellijnen werden gebruikt. Somatische celfusie lag 
het meest voor de hand omdat deze techniek al sinds 1975 met succes gebruikt 
wordt voor de immortalisatie van B-lymfocyten ten behoeve van de produktie van 
mAb. Tijdens het onderzoek werd duidelijk dat immortalisatie van humane 
cytotoxische lymfocyten veel moeilijker is dan van muize B-lymfocyten. 
Proliferatie van mens-mens fusies werd pas 3-6 weken na fusie waargenomen, en 
het aantal hybridomas per fusie was laag (0-30%). In eerste instantie werd 
verondersteld dat de cytotoxische lymfocyten in staat waren de tumor 
fusiepartner tijdens het fusieproces te lyseren, zoals door Kaufmann (144) 
gesuggereerd werd. Op basis van onze resultaten met PEG fusie kunnen wij deze 
mogelijkheid nu uitsluiten (zie Hoofdstuk 4). 
Teneinde het aantal hybridomas per fusie sterk te verhogen werd gebruik 
gemaakt van elektrofusie. Oeze techniek, oorspronkelijk ontwikkeld door 
Zimmermann (153) ten behoeve van de fusie van plantecellen, is door ons 
gemodificeerd voor de produktie van humane cytotoxische hybridomas. Met het 
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door ons ontwikkelde protocol (referentie 151, 152 en Hoofdstuk 4) werden 
lymfocyt en tumorcel gefuseerd in een elektrisch veld. Het voordeel van deze 
methode hoven de PEG fusie is dat het fusieproces onder de microscoop gevolgd 
kan worden. Microscopisch werd waargenomen dat de tumorcel tijdens het 
fusieproces niet gelyseerd wordt door de lymfocyt. Met beide fusiemethoden 
werden prolifererende hybridomas verkregen. Wanneer de T-lymfoma cellijn HSB-1 
als fusiepartner werd gebruikt lag het aantal hybridomas verkregen met 
elektrofusie hoger dan met PEG fusie. Van de 500 mens-mens hybridomas 
verkregen met elektrofusie bleken er drie een lage cytotoxische aktiviteit 
tegen de oorspronkelijke stimulatorcel van de lymfocyt te bezitten, terwijl 
een van de meer dan 100 mens-muis hybridomas een hoge lytische aktiviteit had 
die na drie weken kweken volledig verdwenen was. Uit karyotyperingen van de 
hybridomas en fusiepartners bleek dat zowel mens-mens alsmede mens-muis 
fusieprodukten chromosomen verloren. Gekonkludeerd kon worden dat voornamelijk 
chromosomen van de lymfocyt partner werden uitgestoten omdat de hybridomas in 
bijna alle gevallen de eigenschappen van de tumorcel bezaten en niet die van 
de lymfocyt. In enkele gevallen echter werden membraanantigenen (CD3) 
aangetoond op mens-mens, en MHC determinanten op mens-muis fusieprodukten. 
Deze CD3 antigenen en MHC determinanten waren afkomstig van de T-lymfocyt. Van 
een aantal hybridomas kon het invasieve karakter van de T-lymfocyt-fusie 
partner aangetoond worden. 
De konklusie is dat zowel PEG als elektrofusie uitstekende technieken 
zijn om humane T-cellen te immortaliseren. Door het verlies van een of meer 
chromosomen, waarop de genen liggen die coderen voor de eigenschappen die 
tesamen noodzakelijk zijn voor het lytische proces, blijkt celhybridisatie 
ongeschikt voor immortalisatie van lytische funkties. 
Het injekteren van genen met proliferatieve eigenschappen zou een 
alternatieve strategie kunnen zijn om cytotoxische lymfocyten te 
immortaliseren. Daartoe is echter inzicht nodig in de genen die betrokken zijn 
bij de proliferatie van cytotoxische lymfocyten. Kandidaten hiervoor zijn 
bijvoorbeeld IL-2R c-myc en e-ras genen. In Hoofdstuk 5 is de expressie van 
c-myc en e-ras genen op mRNA niveau en IL-2R op eiwitniveau in gekloneerde 
TCR~~+/CD3+ T-en TCR-/CD3- NK cellen, alsmede in T-lymfoma cellijnen, voor 
en na aktivatie met (PHA, allo-antigenen of met IL-2) beschreven. Uit onze 
resultaten bleek dat het aantal c-myc mRNA produkten en IL-2R na aktivatie van 
de gekloneerde lymfocyten tijdelijk verhoogd was, terwijl in T-lymfoma 
cellijnen alleen c-myc mRNA gevonden werden en geen IL-2R. 
Produktie van c-myc mRNA door stimulatie met IL-2 in normale 
lymfocyten, zoals beschreven door Reed en medewerkers (89), en het permanent 
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produceren van c-myc mRNA in T-lymfoma cellijnen suggereert dat de afwezigheid 
van IL-2R op T-lymfoma cellijnen het gevolg is van het niet meer biologisch 
funktioneel zijn van deze receptoren. Immers, c-myc mRNA wordt al permanent 
geproduceerd in deze cellen, dus de interaktie tussen IL-2 en diens receptor 
voor de induktie van c-myc mRNA produktie is overbodig. Behalve c-myc mRNA en 
IL-2R is ook de produktie van e-ras mRNA bestudeerd in gekloneerde TCR~~+/CD3+ 
Ten TCR-/CD3- NK cellen. De produktie van e-ras mRNA bleek parallel te !open 
met de produktie van c-myc mRNA. Deze resultaten komen overeen met de 
resultaten van Stern en medewerkers (80), die aangetoond hebben dat in humane 
PBL c-myc mRNA alleen geproduceerd wordt als e-ras mRNA ook geproduceerd 
wordt. Ook toonden zij aan dat de aanwezigheid van c-myc en e-ras mRNA in 
humane PBL niet voldoende was om immortalisatie tot stand te brengen. Op grond 
van onze resultaten en recente literatuurgegevens lijkt de kombinatie van myc, 
ras en IL-2R genen op een vector zeer geschikt voor immortalisatie van 
cytotoxische lymfocyten. Onlangs heeft Abken (245) muize cytoplasten met 
sukses gefuseerd met humane lymfocyten. In deze geimmortaliseerde lymfocyten 
was de produktie van e-ras en c-myc alswel P53 mRNA verhoogd, wellicht als 
gevolg van overgedragen extra chromosomale genetische faktoren. Ook deze 
faktoren zouden geschikt kunnen zijn voor immortalisatie• 
Manipulatie van specifieke komponenten van het immuunsysteem met 
"biological response modifiers" (BRM) biedt ook goede mogelijkheden voor 
immuuntherapie. In hoofdstuk 6 is de invloed van BRM (OK-432 en IL-2) op de 
lytische kapaciteit van gekloneerde TCR~~+/CD3+ CTL en TCR-/CD3- NK cellen 
beschreven. Beide typen cellen bleken in staat op OK-432 en IL-2 te reageren; 
verhoging van de lytische kapaciteit werd verkregen na inkubatie van de 
lymfocyten met OK-432 of IL-2. Eerder is beschreven dat alleen TCR-/CD3- NK 
cellen gevoelig zijn voor OK-432. Onze resultaten tonen aan dat ook 
TCR~~+/CD3+ CTL gestimuleerd kunnen worden met BRM. De resultaten beschreven 
in Hoofdstuk 6 tonen aan dat ook de antilichaam-afhankelijke cytotoxiciteit 
van gecloneerde NK cellen en verse PBL (bevat NK cellen) verhoogd kan worden 
met OK-432, maar niet met IL-2. Door verschillende auteurs is gesuggereerd dat 
OK-432 werkzaam is via IL-2 produktie. Onze resultaten suggereren echter, dat 
OK-432 onafhankelijk van IL-2 werkt. 
De resultaten beschreven in dit proefschrift geven inzicht in de 
verschillende typen cytotoxische lymfocyten die in staat zijn tumorcellen te 
lyseren. Deze gegevens, alsmede de gevonden aanwijzingen dat de tumoren 
mogelijk immunogeen kunnen zijn in vivo, verschaffen een basis voor 
immuuntherapie. Geimmortaliseerde cytotoxische lymfocyten kunnen daarbij van 
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essentieel belang zijn. Somatische celhybridisatie blijkt echter ongeschikt 
als methode om immortalisatie te verkrijgen. De overdracht van genen betrokken 
bij de proliferatie van cytotoxische lymfocyten, zoals de genen die koderen 
voor IL-2R c-myc, e-ras en P53, biedt waarschijnlijk betere perspektieven. Een 
alternatief voor het mobiliseren van grote aantallen geimmortaliseerde 
cytotoxische lymfocyten met anti-tumor aktiviteit is het gebruik van 
geselekteerde (gekloneerde) cytotoxische lymfocyten gestimuleerd met BRM zoals 
IL-2 en OK-432, die in staat zijn de lytische kapaciteit van TCR~~+/CD3+ CTL 
en TCR-/CD3 NK cellen te verhogen. Deze gekloneerde TCR~~+/CD3+ CTL en 
TCR-/CD3 NK met verhoogde lytische kapaciteit tegen tumor cellen zouden 
gebruikt kunnen worden voor immunotherapie. 
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ABBREVIATIONS 
ADCC 
AH 
AK 
B-LCL 
BRM 
c 
CD 
CHN 
CTL 
CTX 
D 
EBV 
EGF 
FCS 
FACS 
FCS 
FITC 
HAT 
HD 
HLA 
HTLV 
IFN 
II 
IL-2 
J 
K 
LAK 
LDCC 
LFA 
mAb 
MAF 
MCSF 
MLC 
NK 
PBL 
PDGF 
PEG 
PHA 
R 
SCID 
SDS 
SRBC 
TAA 
TCGF 
TCR 
TRF 
TSTA 
v 
antibody-dependent cellular cytoxicity 
azaserine hypoxanthine 
activated killer 
lymphoblastoid B-cell line 
biological response modifiers 
constant 
cluster differentiation 
channel 
cytotoxic T lymphocytes 
cellular cytotoxicity 
diversity 
Epstein-Barr virus 
epidermal growth factor 
fetal calf serum 
fluorescent activated cell sorter 
fetal calf serum 
fluorescein isothiocyanate 
hypoxanthine aminopterin thymidine 
healthy donor 
human leucocyte antigen 
human T-leukemia virus 
interferon 
infiltration index 
interleukin-2 
joining 
klinische einheiten 
lymphocyte-activated-killing 
lectin-dependent cellular cytoxocicity 
lymphocye function-associated antigen 
monoclonal antibody 
macrophage activating factor 
macrophage colony-stimulating factor 
mixed lymphocyte culture 
natural killer 
peripheral blood lymphocytes 
platelet-derived growth factor 
polyethylene glycol 
phytohaemagglutinin 
receptor 
severe combined immunodeficiency disease 
sodium dodecyl sulfate 
sheep red blood cells 
tumor-associated antigens 
T-cell growth factor 
T-cell receptor 
transferrin receptor 
tumor-specific transplantation antigens 
variable 
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